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ABSTRACT 
In this study the metabolism of the anti-arthritic drug, phenylbuta= 
zone, was investigated in female Wistar rats, and the results 
compared with those of other workers in this field. 
Two interrelated projects were undertaken. The first covered the 
pattern of excretion, isolation and characterisation of the metabo= 
lites and decomposition products of phenylbutazone in rats dosed 
post -orally with the drug. It was found that the major route of 
excretion was via the urine and over 50% of the administered dose 
was excreted in the first 24 hours by this route. A small percentage 
of the dose was excreted in the faeces. The following compounds 
were identified using chromatographic and autoradiographic techniques: 
p-Hydroxy derivative of phenylbutazone 
Y-Hydroxy derivative of phenylbutazone in both its molecular forms 
(ring lactone and straight chain hydroxyl) 
4-Hydroxy derivative of phenylbutazone 
p-Y-Dihydroxy derivative of phenylbutazone 
p-4-Dihydroxy derivative of phenylbutazone 
Hydrolysable conjugates (possibly glucuronides) 
Water soluble non-hydrolysable conjugates. 
The second project dealt with the quantitation of the water insoluble 
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compounds isolated in the initial work. Using a unique technique, 
combining inverse isotope dilution assay and spectrophotometric 
analysis, it was found that the major metabolite was the Y-hydroxy 
derivative of phenylbutazone, present in both its molecular forms. 
Oxyphenbutazone was a minor metabolite and the p-Y-dihydroxy deriva= 
tive of phenylbutazone was present only in very low concentration. 
These results did not conform with those of previous workers in this 
field who reported the Y-hydroxy derivative of phenylbutazone, in 
one molecular form only, as the major metabolite and the dihydroxy 
derivative as the second metabolite with a higher concentration in 
the urine than oxyphenbutazone. This disparity could be due to the 
fact that these workers took no account of the presence of the two 
molecular forms of the Y-hydroxy derivative of phenylbutazone with 
their different polarities and different Rf values. The present 
study showed that the straight chain hydroxyl isomer was probably 
mistakenly identified as the p-Y-dihydroxy derivative of phenylbuta= 
zone. This theory is supported by the fact that the percentage dose 
recovered by the previous workers of the Y-hydroxy and p-Y-dihydroxy 
derivatives together equalled the percentage dose recovered in this 
study of the two molecular forms of the Y-hydroxy derivative. 
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I N T ROD U C T ION 
CHAPTER I 
PYRAZOLIOINE 3,5-DIONES AND DERIVATIVES 
Phenylbutazone is a derivative of pyrazolidine 3,5-dione (Figure 1) 
and has been the subject of extensive investigation as an antiarthritic 
drug. 
Fig. 1 Basic Structure of Phenyl Pyrazol·idine 3,5-dione 
Other related compounds have been investigated as uricosuric and anti-
inflammatory agents. These are listed in Table 1. 
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Table 1 STRUCTURE OF PHENYLBUTAZONE AND RELATED DRUGS 
Number Compound Rl R2 R3 
1 Phenyl butazone H H (CH 2)3CH 3 
2 Y-Hydroxy derivative H H (CH2)2CHDHCH3 
3 p~Y-Dihydroxy derivative OH H (CH2)2CHOHCH3 
4 p-Hydroxy derivative OH H (CH2)3 CH3 (Oxyphenbutazone) 
S p-Nitro derivative N02 H (CH2)3 CH 3 
6 p-p'-Dif1uoro derivative F F (CH 2)lH3 
7 p-p'-Dich1oro derivative C1 C1 (CH 2)3CH3 
8 Dimethy1su1phone derivative CH3S0 2 CH3S02 (CH2)lH3 
9 Isopropyl derivative H H CH(CH3)2 
10 Ethy1su1phoxypheny1 H H (CH2)2S0C6HS derivative 
11 Y-Keto derivative H H (CH 2)EOCH3 
12 Ethy1su1phonypheny1 H H (CH 2 )~02C6HS derivative 
13 Prenazone H H CH 2CH=C( CH3) 2 
14 p- Hydroxy-tertiary butyl OH H C(CH3)3 derivative 
IS p-Hydroxy-isopropy1 OH H CH(CH3)2 derivative 
16 p-p '-Di methy1 derivative CH3 CH 3 (CH2)3CH3 
17 4-Pheny1thioethy1 H H (CH2)3SC6HS derivative 
18 p-Hydroxy-u-keto OH H CO(CH2)2CH3 derivative 
3 
It has been shown that variations in the ring structure, R1 and R2, 
and in the side chain, R3, caLise marked changes in the physico-
chemical properties of these derivatives. These changes, in turn, 
have a direct influence on their pharmacokinetic and therapeutic 
values (15, 18, 24,44, 65). 
The correlation between structure and some of the important pharma= 
cUkinetic and therapeutic values is shown in Table 2. (15, 15, /9,2./, 
14, ?>9, 44, 'te" 55", Sb). 
Plasma binding studies of the derivatives of phenylbutazone with human 
plasma were undertaken (24, 44) using the method described by 
Burns (11). 
I twas fO'und that: 
(i) the majority of the derivatives were highly bound, in the order 
of 98-99%; 
(ii) substitution of a hydroxyl group in the gamma position of the 
side chain reduced the binding capacity of the y-hydroxy and 
p-y-dihydroxy derivatives of phenylbutazone to 94% and 83% 
respectively. However, substitution with other polar groups, 
such as a keto group, in this position had no effect on binding 
(44) • Therefore it appeared that the equilibrium reaction of 
the two molecular forms, one of which was a lactone , reduced 
the drug-protein interaction and thereby lowered the plasma 
binding capacity of the y-hydroxy derivatives .. (Figure 3). 
Tab 1 e 2 
Deriva= 
tive 
Number 
1 
2 
3 
.4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
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PHARMACOKINETIC AND THERAPEUTIC VALUES OF DERIVATIVES 
OF PYRAZOLIDINE 3,5-DIONE 
Plasma 24 h Uricosuric 
Binding Half-life pKa urinary Kp dose 
% h excreti on mg % dose 
Man Dog Man Dog Man 
99 92 72 7 4,5 < 1 2,2 BOO-1 000 
94 85 10 2 4,0 8 0,6 150- 300 
83 63 4 2 4,3 < 50 0,01 
99 89 72 0,5 4,7 < 2 0,6 800-1 000 
98 98 20 12 3,2 < 2 1,0 30- 100 
99 91 40 47 4,5 < 1 1,0 1 500 
99 99 20 33 4,0 < 1 83 1 500 
98 87 1 0,5 2,6 40 0,6 100- 150 
98 96 72 5,0 5,5 < 1 3,4 1 200 -
no effect 
99 90 2,5 2 2,8 43 0,5 30- 70 
98 97 - - 2,0 42 -
-
99 90 3 2 2,7 35 0,5 100 
- 91 20 4,8 5,1 < 0,1 
- -
99 87 1 1 7,1 
- 8,0 -
96 79 12 1 5,8 - 0,4 
-
- - - -
4,9 24 - 1 200 -
no effect 
99 99 3 7 3,9 < 1 1,6 150- 300 
99 91 8 3 2,3 41 0,4 100 
5 
Straight chain hydroxyl isomer Ri ng lactone isomer 
Fig. 2 Molecular Forms of the Y-Hydroxy Derivative of 
. Phenyl butazone 
In man 
The biological half-life of phenylbutazoneAhas been reported as 72 
hours (11). Substitution of the hydroxyl group in the Rl position 
had no effect on the half life, but the introduction of the more 
acidic nitro group reduced the half life to twenty hours (56). 
Derivatives with halides in the Rl and R2 positions also reduced the 
half-life; that of the difluoro derivative to 40 hours and of the 
dichloro derivative to 20 hours (24). Substitution with a highly 
acidic group, such as methylsulphone, in these positions had an even 
more marked effect, reducing the half-life to one hour (24). It 
appeared that there was an inverse relationship between the acidity 
of the substituent and the half-life of the derivative. 
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Substi tuti on of an isopropyl group in the R3 pos iti on also had no 
effect on the half-l ife of phel~yl butazone (24) but, as in the case of 
ring substitution, the introduction of more acidic groups reduced 
the half-life. For example, substitution of a Y-hydroxy group reduced 
the half-life to ten hours (55) and of ethylsulphoxyphenyl to 2~ 
hours (21). 
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There is a strong relationship between renal excretion and the pKa of 
a derivative. Blood is filtered through the glomerular membranes, 
which act as though they had pores 10 nm wide and 50 nm long (47), thus 
preventing excretion of very large molecules, including the plasma 
bound derivatives; therefore the concentration of the non-ionised, 
readily diffusible drug in the glomerular filtrate is very low. 
During the passage of the filtrate through the proximal convoluted 
tubule approximately 99% of the water is re-absorbed (47), thereby 
increasing the concentration of the drug and encouraging its re-
absorption into the peritubular fluid. 
termed non-ionic back diffusion (24). 
This re-absorption has been 
If the drug is ionised, there 
is a very low concentration of unionised molecules in the fluid and 
secretion from the peritubular fluid to the tubular fluid can occur. 
Therefore, derivatives with a low pKa value should be ionised in the 
basic fluid of the proximal convoluted tubules and excretion would be 
expected. In the distal convoluted tubules, where the fluid is acid, 
there is minimal i on isation, thus re-absorption is favoured. These 
theories were confirmed by experimentation in dogs (24). Peak 
secretion occurred in the proximal tubular segments, and re-absorption 
took place principally from the distal tubular segments, though less 
acidic drugs were also re-absorbed in the proximal segments (24). As 
stated earlier, it was found that the majority of the derivatives 
of phenylbutazone were very strongly bound to plasma protein in man 
(24, 44), therefore the quantities in the glomerular filtrate were 
uniformly small and differences in the rate of renal excretion must 
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depend on differences in the rate of tubular secretion and/or re-
absorption. The derivatives with a low pKa value would be ionised 
. in the basic urine of the proximal tubules, thus active secretion 
would be facilitated and the rate of excretion increased . In fact 
it has been shown that such changes in the structure of phenylbutazone 
which decreased the pKa value markedly enhanced urinary excretion (3, 
24, 44). Phenylbutazone had a pKa value of 4,5 and was excreted at 
the rate of less than 1% of the dose in 24 hours in man (24). Sub= 
stitution of a hydroxyl group in the R1 positiD~did not reduce the 
pKa value or the rate of excretion. But substitution in the R1 and 
R2 positions with the acidic methylsulphone group reduced the pKa 
value to 2,6 and caused an increase in the rate of exc retion to 40% 
of the dose in 24 hours (24) . 
Similarly, substitution of acidic groups, such as Y-keto , ethylsulphonyh 
phenyl and ethylsulphoxyphenyl, in the side chain decreased the pKa 
values to 2,0, 2,7 and 2,8 respectively (24). Substituti on of an 
acidic group into the p-hydroxy derivative of phenylbutazone also had 
the effect of reducing the pKa value and increasing the rate of 
excretion. For example the a-keto derivative of oxyphenbutazone was 
found to have a pKa value of 2,3, and 41% of the dose was excreted in 
24 hours (48). Derivatives with a high pKa value would be unionised 
in the proximal tubules, therefore the concentration gradient would 
favour secretion. In fact, it has been reported that some,non-ionic 
back diffusion took place in the proximal tubules and was considerably 
greater in the distal tubules, resulting in a low rate of excretion. 
9 
Thus, the isopropyl and p-p'-difluoro derivatives of phenylbutazone 
and prenazone with pKa values of 5,8, 4,5 and 5,1 had rates of 
excretion of less than 1% of the dose in 24 hours (Table 2). 
The biological half-life and rate of excretion of the derivatives 
of phenylbutazone have been correlated, to a certain extent, with 
their partition co-efficient between peanut oil and buffer of pH 7,4; 
this value was referred to by Perel as Kp (44). It was shown that, 
of the deri vati ves tested, in general those with a Kp value 1 ess than 
0,6 had a biological half-life of under twelve hours . (Table 2). 
It would appear from the foregoing that a low pKa value led to a short 
biological half-life. There were certain anomalies to this as can 
be seen from Table 2. For example the t-butyl-p-hydroxy derivative 
of phenylbutazone had a pKa value of 7,1 and therefore should have 
had a long half-life. In fact, its half-life was extremely short 
(1 hour). However, this derivative was excreted mainly as a glucu= 
ronide (44), and it has been shown that glucuronides have pKa values 
of the same low order as glucuronic acid, viz 3,2 (25). In addition 
this t-butyl-p-hydroxy derivative had the high Kp value of 8,0 (44) 
giving a high lipid solubility which facilitated entry into the 
liver cells, where conjugation produced a compound with a low pKa 
value which could be rapidly excreted . On the other hand, the iso-
propyl-p-hydroxy derivative of phenylbutazone was also excreted as a 
glucuronide but had a much longer half-life . This could be explained 
by the fact that its Kp value (0,4) was much less than that of the 
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t-butyl-p-hydroxy derivative; therefore its entry into liver cells 
would be hindered and thus the, rate of glucuronide formation reduced . 
The p-Y-dihydroxy derivative Gf phenylbutazone also proved an exception 
to the recognised relationship between pKa, half-life and rate of 
excretion. This derivative proved to have a relatively high pKa 
value of 4,3, but was extensively excreted in the urine and had the 
short half-life of four hours . (44). However, it was found to have 
a very low Kp (0,01); this low lipid solubility would prevent facile 
non-ionic back diffusion in the tubules. Also, as aforementioned, 
only 83% ·of this derivative was plasma bound, therefore its concen= 
tration in the glomerular filtrate would be higher than that of the 
more highly bound derivatives. 
Thus it is apparent that the biological half-life and the rate of 
excretion of derivatives of phenylbutazone are dependent on the 
inter-relationship of a number of different factors, such as plasma 
binding, pKa and Kp values. 
Considerable differences in the pharmacological activities of phenyl= 
butazone and its derivatives have been observed (15). It was shown 
.that sUbstitution of a chloro, methyl, nitro or hydroxyl group in the 
para position of the benzene ring resulted in derivatives possessing 
potent anti-rheumatic and sodium retaining activities, whereas sub= 
stitution in the meta position, or in the butyl side chain, produced 
drugs which lacked these therapeutic properties. For example the 
p-hydroxy and p-nitro derivatives of phenylbutazone were found to be 
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as potent oral anti-inflammatory agents as phynylbutazone itself. 
It has also been shown that uricosuric activity was enhanced as the 
pKa value of the derivative increased (15, 24, 44). It was noted 
(13) that derivatives with high pKa values, such as the p-p'-dimethyl 
and isopropyl derivatives of phenylbutazone with pKa values of 4,9 
and 5,5 respectively, had no uricosuric effect in the intravenous 
dose of 1 200 mg. Phenylbutazone (pKa value 4,5) and its p-hydroxy 
derivative (pKa value 4,7) required intravenous doses of 800 to 1 200 
mg to elicit a 100% increase in uric acid clearance. The Y-hydroxy 
(pKa value 4,0) and the 4-phenylthioether (pKa value 3,9) derivatives 
were effective in doses ranging from 300 to 500 mg. The very acidic 
ethylsulphoxyphenyl derivative (pKa value 2,8) was active in doses as 
low as 30 mg. A derivative of particular interest was the p-nitro 
derivative (56). As already stated it proved to have potent anti-
rheumatic and sodium retaining effects. In addition, having a pKa 
value of 3,2, it had pronounced uricosuric activity in dosage as low 
as 30 to 100 mg. 
It thus appears that pharmacological activity can be predicted to a 
large extent from the nature of the substituents in the basic ring 
structure of the pyrazolidine 3,5-diones. Furthermore by processes 
of enzymatic metabolism, the sUbstituents in this basic ring structure 
are modified to give metabolites with little or no pharmacological 
activity and physiological properties favouring their excretion. 
CflAPTER I I 
PHYSICAL PROPERTIES AND DECOMPOSITION OF PHENYLBUTAZONE 
1. SOLUBILITY OF PHENYLBUTAZONE 
Phenylbutazone is almost insoluble in water, but at pH 7,0 the solu= 
bility of the sodium salt is 2,2 mg .ml- 1 (10) . It is readily 
soluble in some organic solvents as shown in Table 3. 
Table 3 SOLUBILITIES OF PHENYLBUTAZONE IN SOME ORGANIC SOLVENTS 
Solvent Sol ubil ity 
Ethyl alcohol 1:28 
Ether 1:15 
Chloroform 1:1.25 
Di ch 1 oromethane > 1:1 
Di chl oroethane > 1:1 
2. POLYMORPHISM OF PHENYLBUTAZONE 
Phenylbutazone has been proved to exist in at least three polymorphic 
forms (I , II, III) with different Differential Scanning Calor imetry 
Fig. 4 
Fig. 5 
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curves and different powder X-ray diffraction patterns (33). (Figures 
4 and 5) 
Mutual transition was observed during heating among the polymorphs. 
as illustrated in Figure 6. 
Fig. 6 
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These findings were important because Forms I and II proved to have 
. different dissolution rates and therefore different bio-availabilities. 
For technical reasons, the dissolution rate for Form III could not be 
determined, but an intermediate form of Form II and form III , desig= 
nated 'pseudo Form III', was tested and had the fastest dissolution 
rate. These dissolution curves are shown in Figure 7. 
The commercially available phenylbutazone is considered to be made 
up of Forms I and II with a melting point of 104 to 1070 C (30) . 
Fig, 7 
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3. DECOMPOSITION OF PHENYLBUTAZONE 
3.1 Forcing Methods of Oxidation of Phenylbutazone 
Workers realised that air oxidation of phenylbutazone occurred 
and the following forcing methods of oxidation were applied to 
determine the products of oxidation formed under varying condi= 
tions as shown in Figures 8, 9 and 10 (3, 23) . 
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3.2 Products of Decomposition of Phenylbutazone Preparations 
In a study of the stability of phenylbutazone in injection and 
suppository form, TLC . techniques were used to isolate the 
various decomposition products shown in Figure 11 (40 , 41). 
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3.3 Routes of Decomposition 
It was found that decomposition products were formed 
through two routes (42). 
3. 3.1 Hydrolysis 
This ;s the principal route of decomposition of phenylbuta= 
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zone in injections and the minor route in suppositories 
(Figure 12), 
P·henylbutazone N - (2-carboxycaproyl) 
hydrazobenzene 
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This is the principal route of decomposition of phenylbuta= 
zone in suppositories and the minor route in injections 
(Figure 13), 
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3.4 Overall Scheme of Decomposition of Phenylbutazone Prepara= 
tions Under Normal Storage Conditions 
Under the relatively mild "conditions of normal storage the pat= 
tern of decomposition has been found to take place as outlined 
in Figure 14 (2). 
3.5 Oxidation of Phenylbutazone on TLC Plates 
Oxidation of Phenylbutazone was shown to take place on TLC plates 
(2. 4). Two products were observed (2). the major one being the 
4-hydroxy derivative of phenylbutazone and the minor one 
N-(~-keto-caproyl) hydrazobenzene. The fact that none of the 
products in the pathway II to VII (Figure 14) were identified 
indicated" that N-(~-keto-caproyl) hydrazobenzene was produced 
directly from the unstable hydroperoxide intermediate shown in 
Figure 15. 
A number of methods have been used for the reduction or pre= 
venti on of on-plate oxidation. One consists of making up 
the slurry with McIlvaine buffer (2). or adding an anti-oxidant 
such as sodium thiosulphate to the slurry (22). Another has 
been to equilibrate TLC plates overnight in sealed plastic bags 
filled with nitrogen (4). 
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CHAPTER III 
PHYSIOLOGICAL PARAMETERS OF PHENYLBUTAZONE 
1. ABSORPTION 
1.1 Extent of Absorption 
In a study of the absorption of phenylbutazone in man (11) plasma 
levels of 8 patients were compared following oral and intramuscu= 
lar administration of single doses of 800 mg of drug . Twenty-
four hours later the levels were found to be approximately the 
same irrespective of the route of administration, which indicated 
that absorption from the gastro-intestinal tract was essentially 
complete (Figure 16). 
In an analysis of stools collected, over a 72 h period, from 
subjects receiving 800 mg phenylbutazone daily less than 5% of 
the daily dose of the drug was found. 
1.2 Rate of Absorption 
The rate of absorption through the gastro-intestinal tract was 
found by measuring plasma levels of patients who receiyed single 
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doses of 800 mg of drug orally. Peak levels were usually 
achieved within 2 h (Figure 16) . When the same patients were 
dosed by the intra-muscular route, peak plasma levels were only 
achieved within 6 to 8 h of injection (Figure 16) (11), This 
slow absorption was proved to be due to localisation of the drug 
at the site of injection due to protein binding in the tissues 
(11) , 
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2. PLASMA PRO TEIN BINDING 
Studies in man (24) showed that, at plasma levels within the thera= 
-1 peutic range of concentration (60 - 150~g . ml ), 98 - 99% of the 
drug was bound to the plasma proteins. At higher levels (250;49.ml - 1), 
only 88% of the drug was bound. Comparative work with dogs proved 
·that in this species protein binding was lower than in humans (92%) 
(Table 2) (44). 
3. TISSUE DISTRIBUTION 
Distribution studies were undertaken in a dog given 50 mg.kg- 1 
phenylbutazone intravenously and sacrificed 3 h later. The concen= 
tration of drug in all tissues was appreciably less than in plasma 
(Table 4). 
Although tissue concentrations were lower than those in whole plasma 
they were considerably higher than those of unbound drug in plasma. 
This indicated a considerable interaction between the drug and tissue 
proteins; hence, the localisation of the drug at the site of intra-
muscular injection (11). 
The tissues of a human subject who received the drug orally for 8 
days prior to death also showed an appreciably higher concentration 
in the plasma than in organ tissue (11) (Table 5). 
Table 4 
Tissue 
Plasma 
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DISTRIBUTION OF PHENYLBUTAZONE IN DOG TISSUES 
(Dog received 50 mg.kg- 1 intraveneously and the 
tissued were examined three hours later) 
Concentration of Phenylbutazone 
mg.kg-1 
79 
Plasma water 2,0 
Red blood cells 9,2 
Lung 15 
Kidney 4B 
Liver 64 
Heart 30 
Muscle 8,1 
Brai n 15 
Lumbodorsal fat 23 
Table 5 
Tissues 
Plasma 
DISTRIBUTION OF PHENYLBUTAZONE IN HUMAN TISSUES 
(Patient received BOO mg phenylbutazone orally for 
several days prior to death, and received the last 
dose of 200 mg about 12 h before death. The tissues 
were removed for analysis within 3 h post mortem) 
Concentration of Phenylbutazone 
mg.kg- 1 
115 
Plasma water 2,3 
Adrena 1 s 80 
Heart 55 
Spleen 37 
Kidney 70 
Lung 78 
Muscle 45 
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4. ' PLASMA LEVELS 
A group of 60 subjects was gi lien 800 mg of phenyl butazone daily for 
14 days or more . It was found that during the first 3 or 4 days 
plasma levels progressively increased, reached a plateau and there= 
after were constant from day to day for a given individual . This 
pleateau level varied from 60 to 150 mg·l- 1 (11). 
5.. EXCRETION 
Seventy-two hour urine samples from human subjects, who had received 
800 mg phenylbutazone by intra-muscular injection, were found to 
contain only traces of the administered drug (ll). Further work 
showed that less than 1% of the dose was excreted as phenylbutazone 
in 24 h urine (24) . 
In order to measure the rate of disappearance 16 human subjects were 
given intra-muscular injections of phenylbutazone, and their drug 
plasma levels measured 24 h later and at various times thereafter . 
The rate of disappearance per person ranged from 10 to 35% ?er day 
with an average of 21% (11). 
As stated above, less than 1% of the dose was excreted as phenylbuta= 
zone in 24 h urine, but the rate of disappearance of the drug from 
the plasma was proved to be approximately 21%, therefore it can be 
inferred that biotransformation takes place and the products of 
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metabolism are excreted. Th 'i s was proved to be the case. Studies 
using counter-current distribution methods, accounted for less than 
10% of the dose of the phenylbutazone administered (13). However, 
the introduction of radio-chemical methods greatly clarified the 
picture. Experiments in rats, using carbon labelled phenylbutazone, 
show'ed that most of the excretion occurred in urine within 24 h. No 
excretion was detected in expired air (43). This was later confirmed 
by ,workers who stated that in rats more than half the administered 
dose was excreted in the urine during the first 24 h. Thereafter 
urinary excretion was less important, and the mean total excretion 
in 48 h amounted to 60,8% of the dose. ,Faecal excretion was re= 
ported as 22,9% in the first 24 hand 11,9% in the second 24 h, a 
total of 34,7%. Again no excretion was detected in the expired air 
(4). Great variation was shown between individual animals with 48 h 
urinary excretion varying from 47,2% to 74,3% and faecal excretion 
from 31,3% to 40,8%. 
Studies . in humans showed a similar pattern. After 21 days 88% of 
the dose was recovered, 61% from urine, 27% from faeces and none from 
expired air (22). 
6. BIOLOGICAL , HALF~LIFE 
The biological half-life of phenylbutazone in man is 72 h (11). 
Comparative studies with animals showed that in all other species 
tested the rate of disappearance of the drug from the plasma was faster 
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than in man (11). Phenylbutazone was administered intravenously to 
dogs and rabbits in -1 . -1 doses of SO mg·kg and 100 mg·kg respectively, 
and intraperitoneally to Wistar rats and Beltsville guinea pigs in 
doses of 100 mg.kg-1. The half-lives were found to be as follows: 
dog 6 h, rabbit 3 h, rat 6 h, guinea pig 5 h. 
It is thought that sex may also affect half-lives, but, so far, the 
rat is the only species in which this has been proved (9). 
CHAPTER IV 
PHENYLBUTAZONe METABOLISM 
1. MECHANISM OF METABOLISM 
It would appear that phenylbutazone is mainly metabolised by liver 
microsomes through Phase I and Phase II reactions (4, 13, 22, 32, 43). 
1.1 Phase I Reactions 
The Phase I reactions are largely hydroxylations effected by the 
mixed function oxidase system following the possible mechanism 
shown in Figure 17. 
Two mechanisms of hydroxylation occur in phenylbutazone, either 
hydroxylation of the carbon atom in the para position in the 
aromatic ring to give oxyphenbutazone as a metabolic product, 
or hydroxylation of the w-l carbon atom in the butyl side chain 
to give the Y-hydroxy derivative of phenylbutazone as a meta= 
bolite. These mechanisms of hydroxylation possibly follow in= 
dependent pathways and utilise different enzyme systems . The 
results of studies suggest that butyl side chain hydroxylation 
is the major pathway -of Phase I metabolism in phenylbutazone 
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(4, 13, 22, 32). The p-Y-dihydroxy derivative of phenylbuta= 
zone has also been detected as a metabolite (4, 22). 
The products of Phase I hydroxylation may then be either excreted 
or further· metabolised. 
1.2 Phase II Reactions 
Metabolic products which could be hydrolysed by . ~-glucuronidase/ 
arylsulphatase were detected in urine and faeces (4). These 
metabolites were therefore ~-glucuronides or sulphates synthe= 
sised by liver microsomes utilising Phase II conjugation 
mechanisms. Such conjugations require an agent, which must be 
in an active for~ and a transferring enzyme. 
1.2.1 O-Glucuronide Conjugation 
In O-glucuronide formation the agent, glucuronic acid, is 
activated to form uridine diphosphate glucuronic acid 
(UDPGA) and the concentration of the enzyme, UDP glucuronyl 
transferase, is elevated in the vi ci nity of cytochrome 
P450, where the mfo reactions are taking place (27). The 
mechanisms of glucuronide formation of the hydroxy deriva= 
tives of phenylbutazone are shown in Figure 18. It is 
possible that different glucuronyl transferases take part 
in glucuronide formation as shown in Figure 18 1 and 2. 
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1. 2.2 O-Sulphate Conjugation 
In sulphate conjugation the agent, S04-' is activated by a 
series of actions involving ATP to form 3'-phosphoadenosine-
5'-phosphosulphate (PAPS) which, in the presence of the 
enzyme sulphokinase, acts with the product of Phase I meta~ 
bolism as shown in Figure 19 (28). Similarly, it is 
possible that different sulphokinases are involved in the 
conjugation of the phenolic hydroxyl group and the alcoholic 
group in the butyl side chain. 
1. 2.3 C-4-Glucuronide Conjugation 
Another mechanism of conjugation results in the formation of 
C-4-glucuronides (21, 22). 
been elucidated. 
This mechanism has not yet 
1. 2.4 Excretion of the Products of Phase II Reactions 
Excretion of the products of conjugation can be via the 
urine or through the enterohepatic circulation in which 
substances of high molecular mass are transported to the 
intestine in the bile. 
2. REPORTED METABOLITES OF PHENYLBUTAZONE 
Early work on the metabolism of phenylbutazone showed the presence of 
two urinary metabolites, oxyphenbutazone and the Y- hydroxy derivative 
(12) (Figure 20). 
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The presence of these metabolites was confirmed in later studies in rats 
and humans using labelled drugs (1, 4, 22, 35). Following studies on , 
the metabolism of keto-phenylbutazone (38) where the dihydroxy deriva= 
tive was proved to be a major metabolite, it was suggested that a 
dihydroxy derivative could also be a metabolite of phenylbutazone. 
Bakke (4) reported the presence of this derivative (Figure 21) as a 
major metabolite in the urine of rats dosed with phenylbutazone and 
postulated the theory that it was formed by a mechanism shown in 
Figure 22. 
The presence of this derivative has also been reported as a minor 
metabolite in humans (22). 
( 
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Structure of the p-Y-dihydroxy Derivative of 
Phenylbutazone 
The 4-hydroxy derivatives of phenylbutazone and oxyphenbutazone 
(Figure 23) have been isolated from the urine of rats, but it has not 
been determined whether they are metabolites or artifacts (4). 
Reports on the presence of metabolic conjugates in both rats and 
humans have been mentioned in literature. 
In experiments in rats the presence of small amounts of O-conjugates, 
chiefly glucuronides, of oxyphenbutazone and the Y-hydroxy and p-Y-
dihydroxy derivatives of phenylbutazone were reported in the urine, 
amounting' to not more than about 2,7% of the administered dose. In 
the bile, conjugates amounted to about 4,2% of the dose (Figure 25) 
(4) • 
99 
N-N 
I I 
99 
N--N 
I I 
o=c c=o 
"c/ 
H/ "CH -CH -CH-CH 
2 2, 3~ 
o=c c=o 
"c/ ~ 
H/"CH ~ 
" 9 
Phenylbutazone 9~ 
N--N 
I I 
o=c c=o 
"c/ 
H/ "c H 
OH . OH ~ 
V-Hydroxy derivative ~ 99 
" 9 ~YPhenbutazone 
of phenylbutazone 
Fi 9 _ 22 
N--N VI I I 
o=c c=o 
___ .......,;:.. Conjugates 
"c/ 
H/ "CH -CH -CH-CH 2 2, 3 
OH 
p-y-Oihydroxy derivative 
of phenylbutazone 
Formation of the Dihydroxy Derivative of Phenylbutazone 
w 
'" 
Fi g. 23 
40 
99 
N-N 
I I 
o=c c=o 
~c/ 
HO/ "-c H 
" 9 
4-Hydroxy derivative 
of phenylbutazone 
9~ 
N--N 
I I 
O=C C=O 
"C/ 
/"-HO C4H9 
4-Hydroxy derivative 
of oxyphenbutazone 
Structure of the 4-Hydroxy Derivatives of Phenylbutazone 
and Oxyphenbutazone 
99 
N--N 
I I 
9~ 
N--N 
o=c c=o 
I I 
O=C C=O ~c/ 
H/ "-CH -CH -CO - CH 2 2 3 
Y -Keto derivative 
of phenylbutazone 
~C/ 
H/ "-CH2-CH2-CO-CH3 
Y - Keto derivative 
of oxyphenbutazone 
Fig. 24 . Structure of the v-Keto Derivatives of Phenylbuta= 
zone and Oxyphenbutazone 
I 
I 
I 
I 
I 
I 
I 
I 
I 
Fi g. 25 
HOOC--,<-
9~ 
N-N 
II 
O"'C C=O 
""C/ 
H/ ""C H ~ 9 
o 
41 
O-Glucuronide of oxyphenbutazone 
o 
HOOC 
O-Glucuronide of the Y-hydroxy 
derivative of phenylbutazone 
OH 
O-Glucuronides of Derivatives of Phenylbutazone 
42 
In experiments on humans the presence of an a-glucuronide of oxy= 
. phenbutazone was reported (22) but only in small amounts. However, 
1 arge amounts of C-4-gl ucuron.i des of phenyl butazone and the 
Y-hydroxy derivative of phenylbutazone were found. These metabolites 
contained pyrazolidine rings directly attached to glucuronic acid by 
a C-C bond, representing a novel class of drug metabolites (Figure 26). 
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Fi g. 26 Structure of C-4-Glucuronide of Phenylbutazone 
3. HUMAN STUDIES 
3.1 Urine 
Early workers (13) reported that only 8% of the dose of 
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phenylbutazone was excreted in the urine in the form of the me= 
tabolites, oxyphenbutazone and the Y-hydroxy derivative of 
phenyl butazone. Later workers (22), using radio-chemical 
techniques, recovered 61% of the dose in 21 days, made up of 
non-conjugated metabolites, hydrolysable conjugates and non-
hydrolysable conjugates (Table 6). The major portion of this 
radioactivity was in the form of C-4 conjugates, which would 
not have been apparent to the earlier workers with their less 
sophisticated techniques. 
Table 6 RADIOACTIVITY RECOVERED FROM THE URINE OF HUMANS DOSED 
WITH PHENYLBUTAZONE 
Compound % ot .aose administered 
Phenyl butazone 1 ess than 0,7 
Oxyphenbutazone 1 ess than 0)7 
Y-Hydroxy derivative of Z,I phenyl butazone 
p-Y- Dihydroxy derivative 4,0 of phenylbutazone 
Hydrolysable conjugates 0,7 
C-4 conjugates 39,0 
U."i~e",ti tie.d ""c-\:"'" sol v-b ks 14 0 
3.2 Faeces 
The same workers (22) recovered 27% of the dose from the faeces 
collected during 21 days, giving a total recovery of 88% 
(Fi gure 27). 
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4. STUDIES IN THE RAT 
4.1 Urine 
A report that rats dosed with 14C phenylbutazone excreted most 
of the radioactivity in 0 - 24 h urine (43) was confirmed by 
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later workers (4. 32). In both cases over 50% of the total 
radioactivity was recovered in the ·.first 24 h; thereafter the 
radioactivity dropped considerably (Tables 7 & 8). 
4.2 FaeCes 
Workers studying excretion of radioactivity via the faeces 
presented different pictures. In one case (4). twice as much 
radioactivity was excreted in the first 24 h than in the 
second 24 h. and a total recovery of 34,7% was recorded over 
48 h (Table 7) . In another case (32) slightly more radio= 
activity was excreted in the second 24 h period, and a total 
recovery of 9,4% was recorded over 120 h (Table 8). 
4.3 Expired Air 
Early studies in which rats were dosed with 14C phenylbutazone 
indicated that the drug was not metabolised to carbon dioxide 
(42). This was corroborated by other workers (4, 32). who 
reported no detectable excretion of carbon dioxide. 
Table 7 EXCRETION IN RATS DOSED POST-ORALLY WITH 14C-PHENYLBUTAZONE (4) 
% of Administered Dose 
Route 
o - 24 h 24 - 48 h o - 48 h 
Urine 54,3 (44,0-67,4) 6,5 ( 3,2- 8,9) 60,8 (47,2- 74,3) 
Faeces 22,9 (16,3-34,0) 11,8 ( 6,8-17,2) 34,7 (31,3- 40,8) 
Tota 1 Recovery 77,2 (60,3-89,2) 18,3 (10,0-26,1) 95,5 (86,4-105,6) 
Table 8 EXCRETION IN RATS DOSED POST -ORALLY HITH 14C_ PHENYLBUTAZONE (32) 
% of Administered Dose 
Route 
o - 24 h 24 - 48 h 48 - 72 h 72 - 120 h o - 120 h 
Urine 50,2 (46,8-52,5) 12,9 (12,8-13,1) 2,4 (1,9-2,8) 1,8 (1,0-3,0) 67,4 (65,4-68,6) 
Faeces 3,6 ( 3,3- 4,2) 4,3 ( 3,7- 5,4) 0,9 (0,8-1,2) 0,4 (0,3-0,5) 9,4 ( 8,5-11,O) 
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CHAPTER V 
DETECTION AND QUANTITATION OF PHENYLBUTAZONE AND 
ITS METABOLITES 
1. INTRODUCTION 
Early work by Burns (13) on the metabolism of phenylbutazone in man, 
. using transfer counter current distribution techniques, showed the 
presence of two metabolites in the urine of human subjects who had 
been dosed with phenylbutazone. These were the p-hydroxy and 
Y-hydroxy derivatives of phenylbutazone. These metabolites were 
identified by melting point determinations, ultraviolet spectro= 
photometry in sodium hydroxide solution (mNaOH = 2,5 mol.kg-
1) and 
infrared spectrophotometry in chloroform. The method of quantita= 
tion was based on isolation of the metabolites by counter current 
distribution, using equal volumes of ethylene dichloride and aqueous 
phosphate buffer, crystallisation of the precipitate recovered from 
specified funnels and weighing the dried and washed crystals. 
Variation of the pH of the phosphate buffer determined which metabo= 
lite would be precipitated. The total amounts of the metabolites 
present were calculated by application of the binominal expansion in 
the manner described by Williams and Craig (1947). By this procedure 
it was found that the p-hydroxy derivative constituted 3% and the 
4B 
Y-hydroxy derivative 5% of th~ total dose. In the same year (1955) 
these workers (12) studied the metabolism of phenylbutazone in rats 
using 4_14C-phenylbutazone and obtained evidence for the presence of 
other, more water soluble, transformation products of the drug. 
This work was confirmed by Perel (43) in 1961 who, in similar experi= 
ments using 14C-phenylbutazone, found most of the activity in 0 to 
24 h urine; part of this activity was in the form of unknown polar 
metabo 1 i tes ·. In later studies in 1964 (44) they showed that the 
gl ucuroni de of the p-hydroxy deri vati ve was one of these polar meta= 
bo 1 i tes . No further work was reported on the metabolism of phenyl= 
butazone until after 1974 when more specific and accurate techniques, 
using radio-chemical methods, were utilised by Bakke (4), Dieterle 
(22), McGilveray (35) and Aarbakke (1). 
2. ULTRAVIOLET SPECTROPHOTOMETRY 
UV absorption spectra have been used for many years in the quantita= 
tive analysis of phenylbutazone, oxyphenbutazone and the Y-hydroxy 
derivative of phenylbutazone. The aqueous alkali extract of the 
compounds showed pronounced peaks at 265 nm, 255 nm and 262 nm 
respectively (11). 
On binding to human serum albumin, the absorption maxima of phenyl= 
butazone was shifted to 270 nm (16). and the difference spectra 
generated by this shift showed a positive maximum at 2B5 nm (Figure 
28). 
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The absorption spectra of phenylbutazone and oxyphenbutazone were 
also shifted when they were dissolved in organic solvents; ethanolic 
(16) and methanolic (22) solutions were both found to have their 
maxima at 270 nm. 
3. THIN LAYER CHROMATOGRAPHY 
TLC has been used to determine the products of decomposition of 
phenylbutazone, as reported in Chapter II . In 1974 Bakke (4) used 
this technique to characterise and isolate the metabolites of 
phenyl butazone. In order to minimise the effects of oxidation TLC 
50 
was carried out under nitrogen as follows: Pre-coated Merck silica 
gel 60 F254 plates were equilibrated overnight in sealed plastic bags 
filled with nitrogen. Dichloroethane extracts of urine from rats 
dosed with 14C-phenylbutazone were applied to the plates with a 
Hamilton syringe through the plastic bags, and the spots dried in a 
stream bf nitrogen. The plates were transferml to chromatographic 
tanks equilibrated with solvent and nitrogen using the following 
solvents: 
A - Cyclohexane:chloroform:methanol:acetic acid (60:30:5:5) 
B - Dichloroethane:acetone (9:1). 
The metabolites were characterised by comparison with authentic 
standards as shown in Figure 29 and Table 9. 
The 4-hydroxy derivative of phenylbutazone was said to be the main 
decomposition product of phenylbutazone and the 4-hydroxy-oxy 
derivative the major decomposition product of oxyphenbutazone. 
After hydrolysis of the aqueous extract of the urine with 
8-glucuronidase/arylsulfatase the conjugates of oxyphenbutazone, 
and the Y-hydroxy and di-hydroxy derivatives of phenylbutazone 
were isolated. 
4. THIN LAYER CHROMATOGRAPHY AND AUTORADIOGRAPHY 
In his studies on the metabolism of phenylbutazone in man, Dieterle 
(22) combined TLC with autoradiography to isolate the metabolites 
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Spray - 0,5% potassium dichromate in 20% sulphuric acid 
as follows: 
Urine from a human male was pre-concentrated by column chromatography 
on Amberlite XAD- 2 resin to produce a metabolite mixture_ Samples 
of this mixture were spotted on commercial silica gel plates 
(Antec SL 254) and developed two-dimensionally, in a nitrogen 
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Table 9 B.f VALUES AND COLOUR REACTIONS OF PHENYLBUTAZONE, 
ITS METABOLITES AND POSSIBLE DECOMPOSITION PRODUCTS (4) 
Rf Values Colour Reactions 
Compounds K2Cr 207 Solvent Solvent Chlorine A B and heat 
Phenyl butazone 0,77 0,82 Green None 
grey 
Oxyphenbutazone 0,39 0,50 Yell ow Yell ow 
Y-Hydroxyphenylbutazone. 0,43 0,05 Violet Brown 
brown 
Di hydroxyphenyl butazone. 0,13 0,00 Yellow Yellow 
4-Hydroxyphenylbutazone ' 0,46 0,57 Green None 
grey 
4-Hydroxyoxyphen=, 0,19 0,10 Yell ow Yellow butazone 
atmosphere to prevent on-plate oxidation, with cyclohexane:chloroform: 
methanol:acetic acid (60:30:5:5) in one direction followed by 
chloroform:acetone:methanol (70:20:10) at right angles . The radio= 
active spots on the plates were visualised by autoradiography and 
compared with the positions of similarly chromatographed reference 
compounds (Figure 30). This method had the advantage of characteri= 
sing the polar, including the non-hydrolysable C-4 glucuronides, and 
the non-polar metabolites concurrently. 
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5. GAS CHROMATOGRAPHY 
Gas chromatography has proved a useful tool in the identification 
(4, 50) and quantitation (1, 34, 36, 37, 53) of phenylbutazone and 
some of its metabolites . The compounds were converted either to 
their trimethylsilyl (TMS) derivatives by reaction with N,O-bis 
(trimethylsilyl) acetamide (BSA) in pyridine (2:1) (1,4,50), or to 
their methyl derivatives by reaction with trimethylanilinium 
hydroxide (36, 37) (Figure 31) and their retention times compared 
with those of standards (Table 10). 
Fig. 31 
Table 10 
Compound 
Phenyl butazone 
Oxyphenbuta= 
zone 
Y-Hydroxy 
derivative of 
phenylbuta~one 
p-Y-Di hydroxy 
derivative of 
phenyl butazone 
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General Formula of TMS and Methyl Derivatives of 
Phenylbutazone and Its Metabolites 
FORMULAE AND RETE NTION TIMES OF DERIVATIVES OF 
PHENYLBUTAZONE AND SOME OF ITS METABOLITES 
TMS Derivative Methyl Derivative 
Reten= Reten= 
Rl R2 R3 tion Rl R2 R3 tion 
Time Time 
OTMS H H 3,5 OCH3 H H 7,1 
OTMS OTMS H 8,2 OCH3 OCH3 H 9,3 
OTMS H OTMS 6, 5 OCH3 H OCH 3 10,6 
OTMS OTMS OTMS 14 ,6 OCH3 OCH 3 OCH 3 
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For quantitation peak height ratios were calculated and compared 
with calibration curves constructed from the results obtained from 
spiked control plasma samples (34, 36, 37). 
6. MASS SPECTROMETRY 
Several workers have studied the fragmentation pattern of phenylbuta= 
zone and some of its metabolites, and these patterns have proved to 
be useful means of identification (2, 49, 51). 
6.1 Phenylbutazone and Oxyphenbutazone 
The mass spectra of phenylbutazone and oxyphenbutazone are 
shown in Figures 32 and 33. 
Locock (29) studied the fragmentation pattern of phenylbutazone 
and oxyphenbutazone and reported the following results with 
m/e for oxyphenbutazone given in parenthesis . 
The compounds were observed to undergo the McLafferty re-
arrangement (51) to give radical ions at m/e 252 (258). This 
was a direct fragmentat i on of the molecular ion with the loss 
of the elements of butene (Figure 34). 
A minor fragmentation pathway for the molecular ions of these 
compounds which was substanti ated by the presence of metastable 
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Fig. 34 McLafferty Re- arrangement of Phenylbutazone 
ions, was the loss of a propyl radical from the butyl side 
chain of the molecular ion to give ions at m/e 265 (281) . 
The most characteristic fragments in the mass spectrum of 
+ 
• 
phenylbutazone (oxyphenbutazone) were a series of peaks at m/e 
182,183,184 and 185 (198,199,200). Table 11 shows the 
relative abundance of these peaks. 
The peak at m/e 182 (198) was attributed to the formation of 
the azobenzene radical ion (C6H5N2C6H5)+ ' 
The ion at m/e 183 (199) could originate f rom the molecular ion 
in the McLafferty re-arrangement radi ca 1 ion (m/e 252 (324)) by 
hydrogen transfer as depicted in Figure 35. 
Tabl e 11 
m/e 
182 
183 
184 
185 
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RELATIVE ABUNDANCE (%) OF FRAGMENT IONS IN THE RANGE 
m/e i82-185 (198, 199, 200) 
Phenylbutazone Oxyphenbutazone 
Relative abundance % m/e Relative abundance % 
2,3 198 6,8 
65,1 199 100,0 
19,8 200 17,7 
2,1 
+ 
. 
m/e 183 
+ 
m/e 252 
Fi g. 35 . Mechanism for Formation of Ion atm/eUH (199) 
A further characteristic fragmentation was the loss of the ele= 
ments of phenyl isocyanate to form the radical ion (C6H5NCO)+ 
m/e 119 or as a neutral molecule (Figure 36). 
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Fi g. 36 Fragmentation Involving Loss of C~5NCO as a Neutral 
Molecule 
6.2 C-4 Glucuronides 
In the structure elucidation of the non-hydrolysable water 
soluble metabolites present in the urine of humans treated with 
14C-phenylbutazone, Dieterle (22) used the technique of mass 
spectrometry. The compounds were converted to their methyl 
ester derivatives and these were subjected to mass spectrometry. 
The presence of the glucuronyl residue was evidenced by molecular 
ions at m/e 498 and 514 together with aglycone fragments at 
308 and 324. 
7. GAS CHROMATOGRAPHY/MASS SPECTROMETRY 
Several workers (1, 4, 36, 37) have used the combination of GC/MS. 
The m/e of the molecular ion and the most abundant ion of phenylbuta= 
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zone, its metabolites and their TMS and methyl ,derivatives are shown 
in Table 12. 
Table' 12 ~10LECULAR ION AND ABUNDANT ION OF PHENYLBUTAZONE, ITS 
METABOLITES AND THEIR TMS AND METHYL DERIVATIVES 
Compound 
Phenylbutazone 
Phenylbutazone - TMS derivative 
• CH3 derivative 
Oxyphenbutazone 
Oxyphenbutazone - TMS derivative 
- CH3 derivative 
y-Hydroxy derivative of phenylbutazone 
Y·OTMS Derivative of phenylbutazone 
Y-CH3 Derivative of phenylbutazone 
p-y-diOH Derivative of phenylbutazone 
p-y-diOTMS Derivative of phenylbutazone 
p-y-di-CH3 Derivative of phenylbutazone 
Molecular 
lone m/e 
308 
381 
322 
324 
468 
352 
324 
460 
352 
340 
556 
366 
Most 
Abundant 
Ion m/e 
183/184 
183/184 
183/184 
199/200 
271/272 
213/214 
183/184 
183/184 
183/184 
199/200 
271/272 
213/214 
It can be seen from Table 12 that, with the knowledge of the m/e of 
the molecular ion and most abundant ion, it is possible to distinguish 
one of these compounds from another. A closer inspection of the mass 
spectra would give a positive identification. 
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8. LIQUID SCINTILLATION SPECTROMETRY 
8.1 Crystallisation and Inverse Isotope Dilution 
In his studies on the metabolism of phenylbutazone in rats 
Bakke (4) used the following technique, combining crystallisation 
and inverse isotope dilution, to isolate and quantitate the 
. phenylbutazone and oxyphenbutazone present in urine. 
A sample of urine (.5 ml) from rats dosed with 14C labelled 
phenylbutazone was added to a buffered (pH 8) aqueous solution 
of 200 mg unlabelled phenylbutazone. A second 5 ml sample of 
urine was added to a buffered solution of 200 mg of unlabelled 
oxyphenbutazone. The compounds were precipitated with hydro: 
chloric acid (mHCl : 1 mol .kg-
1), the mi xture centrifuged and 
the residues dissolved in hot methanol. The solutions were 
filtered and repeated crystallisations were carried out from 
aqueous methanol. Constant specific activity was attained 
after 6 to 7 recrystallisat ions and it was calculated that 
phenylbutazone and oxyphenbutazone accounted for only 0,5 - 1% 
and 2 - 4% of the urinary activity respectively (Table 13). 
8.2 TLC and Liquid Scintillation Spectrometry 
In order to quantitate their major metabolites, the Y- hydroxy 
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and p-Y-dihydroxy derivatives of phenylbutazone, and the artifact, 
4-hydroxy derivative of oxyphenbutazone, Bakke (4) eluted these 
compounds from thin layer chromatograms, which had been developed 
in the solvent cyclohexane:chloroform:methanol :acetic acid 
(60:30:5:5), and counted their radioactivity in the liquid 
scintillation spectrometer. Table 13 lists the % radioactivity 
in the urine and % of the dose of these compounds. 
Table 13 ESTIMATION OF RADIOACTIVE COMPOUNDS IN 0-24 h URINE 
AFTER DOSING WITH 14C PHENYLBUTAZONE BY STOMACH TUBE 
Compound % Activity in % of Dose Uri ne 
Phenylbutazone 0,5 - 1 approx: 0,4 . 
Oxyphenbutazone 3 1,6 
Y-Hydroxy derivative of 46,7 25,4 phenylbutazone 
p-Y-Dihydroxy derivative of 1B,7 10,2 phenyl butazone 
4-Hydroxy derivative of 3,3 1,B oxyphenbutazone 
B,3 TLC, Spectrophotometry and Inverse Isotope Dilution Assay 
In his studies on the metabolism of phenylbutazone in humans, 
Dieterle (22) evolved the following effective method of isolation 
and quantitation of metabolites which permitted simultaneous 
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specific analysis of phenylbutazone, oxyphenbutazone and the 
"Y-hydroxy and p-"Y-dihydroxy derivatives of phenylbutazone in the 
same sample of urine. 
Uri ne (10 ml) was mi xed wi th 20 ml of sodi um thi osul phate 
(mN S 0 = 0,1 mol.kg-
1) and 5 ml of a methanol solution of 
a2 2 3 
10 mg of each of the 4 non-labelled compounds to be determined. 
The isotopically diluted compounds were extracted with methylene 
chloride after evaporation of the methanol, then separated and 
purified by preparative chromatography on thin layer plates 
(0,55 mm) prepared from silica gel 60 PF254 (Merck) containing 
10% sodium thiosulphate. The plates were successively developed 
in solvent system 1 - chloroform:acetone (40:10) - and, after 
drying, with solvent system 2 - heptane:acetone:chloroform: 
acetic acid (55 :35:30:1) - in the same direction. The indivi= 
dual substances were eluted with methanol and re-chromatographed 
with solvent system 2. From the measurement of absorbance at 
270 nm and radioactivity the amount of individual metabolites 
present in the urine was calculated. 
It was found that the contents of phenylbutazone and oxyphenbu= 
tazone both accounted for less than 1,1% of the urinary activity 
and the p-y-dihydroxy and "Y-hydroxy derivatives occured in 
maximum amounts of 6,5 and 3,4% respectively so that the sum of 
phenyl butazone and its non-water sol ub 1 e met abo 1 i tes amounted 
to only about 10% of the urinary activity. 
METHODS 
CHAPTER VI 
APPARATUS AND MATERIALS USED IN EXPERIMENTAL WORK 
1. . APPARATUS USED IN EXPERIMENTAL WORK 
1.1 Liquid Scintillation Spectrometer 
Intertechnique liquid scintillation spectrometer Model SL 
30, with three analyses windows, A, Band C, which have the 
following three settings : 
A 3H/ 14c 3H/32p 
B no pre-setting 
C 3H 14C 
1.2 Teletypewriter 
Teletype teletypewriter (RO) set connected to liquid 
scintillation spectrometer . 
1.3 Spectrophotometer 
Hitachi spectrophotometer Model 101 UV-VIS. 
1.4 Centrifuge 
Chriss centrifuge type UJ IS. 
Sol i d food ' .. ' ,~ , 
dispenser ,,- , ~~ 
Urine collection p , .... :1-"'" 
vessel , ~ , 
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1. 5 Rotavator 
Herdolph rotavator type 51111. 
1.6 Homogeni ser 
Herdolph homogeniser type 50111. 
1.7 , Chromatocharger 
Camag chromatocharger . 
, 1. 8 Freeze Dryer 
Chriss gamma freeze dryer type 26D. 
1. 9 Animal Cage 
Jencon 'Metabowl '. (Fig. 37) 
2. ' MATERIALS USED IN EXPERIMENTAL WORK 
2.1 Reference Standards 
2.1.1 
2.1. 2 
2.1. 3 
Phenylbutazone donated by Ciba Geigy, Basel . 
Oxyphenbutazone donated by Ciba Geigy, Basel. 
y·-Hydroxy derivative of phenylbutazone synthe= 
sised by Dr. H Igel in the Pharmacy Department 
of the University of Durban-Westville. 
2.1.4 
2.1. 5 
2.1.6 
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p-Y-Dihydroxy derivative of phenylbutazone 
donated by Ciba Geigy, Basel. 
4-Hydroxy derivative of phenylbutazone synthesised 
by Professor G.E.A. Mathew. 
14C Labelled phenylbutazone synthesised by 
Professor G.E . A. Mathew. 
2.2 Scintillants 
2.2.1 Bray's scintillant prepared according to the 
method of Bray. 
2.2.2 
2.3 Enzymes 
2.3.1 
2;3.2 
Aquagel™ produced by Chemlab (Pty) Ltd. 
B-Glucuronidase/arylsulfatase produced by 
Boehringer Mannnei ,.--, 
Phenolphthalein mono-B-glucuronic acid 
cinchonidine salt produced by Sigma Chemical 
Company. 
2.4 'TLC Materials 
2.4.1 Pre-coated TLC Plates 
Merck pre-coated TLC Plates Silica gel 60.F254 • 
2.4.2 
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Pre-coated Cherrie Erzeugnisse AG DSF A plates. 
Materials for preparing TLC Plates 
Merck Silica gel GF254 . 
Merck Silica gel PF254 • 
3 .. · ANIMALS USED IN EXPERIMENTAL WORK 
Female Wistar rats weighing between 180 and 200 g obtained from 
the Natal ·Institute of Immunology, certified a pure bred strain. 
CHAPTER VII 
THIN LAYER CHROMATOGRAPHY 
1. PREPARATION OF THE PLATES 
For the initial thin layer chromatography experiments 20 x 20 cm pre-
coated Merck Silica gel 60 F254 plates were cut into squares of 
5 x 5 em using a perspex template as shown in Figure 38; 
e e e 
o-Scm- -5 em ... 4-5 em ...... 
-
cm--A 
IJ. 
0-- • • Removabl. Itop 
e e c 
u u u 
t t t 
t • t 
20 i i i n n n 
em 9 9 9 
_PLATE 
9 9 9 
u u u 
i i i 
d d d 
e e e 
1 
o· . • • Removabl. Itop 
C B 
e e a 
Fig. 38 
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The plate was slid into the area ABCD under the cutting guides and 
kept in position by removable stops. It was cut along the cutting 
guide with a diamond cutter a~d the resultant 20 x 5 cm plates re= 
moved, replaced at right angles in the template and cut again, thus 
forming 5 x 5 cm plates. 
For development these plates were held by jumbo clips and placed in 
23 ml of solvent in a 250 ml beaker . 
Thi s method gave the requi red da ta for pre 1 i mi nary tests and was 
economical in the use of plates and solvents. However, it was not 
considered to be sufficiently accurate to give consistent Rf 
values. In order to improve this technique the following method 
was evolved and, except when otherwise stated, adopted as standard 
procedure in all subsequent experiments using TLC techniques. 
One per cent solutions of reference standards in dichloromethane were 
applied 1 cm from the base of chromatographic plates, 20 cm in 
length, which were developed in the rel evant solvent system until 
the solvent front had advanced to 15 cm from the origin. The 
plates were then dried with the aid of a hair dryer at room tempera= 
ture and sprayed with the selected spray reagent. The colours of 
the developed spots were observed and the Rf values calculated and 
recorded. 
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2. EVALUATION OF SUITABILITY OF SPRAY SYSTEMS 
The spray systems listed in Table 14 were investigated to determine 
the best method of characterising phenylbutazone and oxyphenbutazone 
on chromatograms. 
Table 14 SPRAY SYSTEMS TESTED TO CHARACTERISE PHENYL= 
BUTAZONE AND OXYPHENBUTAZONE 
A 
B 
C 
D 
E 
5% Ferric chloride aqueous solution 
Acetic acid (mCH COOH = 5 mol 'kg-1) 
3 l\. 
5% Potassium ferricy~ide aqueous solution 
10% Ferric chloride aqueous solution 
Water 
1% Potassium permanganate aqueous solution 
2% Sodium carbonate aqueous solution 
Potassium permanganate (mKMno =0,1 mol.kg- 1) 
A t ' ' d ( 4 -1 ce lC aCl mCH COOH = 5 mol'kg ) 
. 3 
Spray with 0,5% potassium permanganate solution, 
foll owed by 
1% Ferric nitrate solution 
equal parts 
1 part 
2 parts 
8 parts 
equal parts 
equal parts 
F 5% Potassium dichromate in 40% aqueous sulphuric acid, 
then heat at 1050 C for 3 minutes 
G 0,5% Potassium dichromate in 20% sulphuric acid, 
followed by 
concentrated sulphuric acid 
H 0,5% Potassium dichromate in 20% sulphuric acid, 
then heat at 1050C for 3 minutes 
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I Ehrlich's reagent 
J Folin Ciocalteau reagent 
K 1% Ferric chloride aqueous solution 
L 0,1% 7-Chloro-4-nitrobenzofuran in chloroform 
M Dragendorff' s reagent 
N Iodoplatinate reagent 
o FPN reagent 
P Mandelin's reagent 
Q Marquis' reagent 
One per cent solutions of phenylbutazone and oxyphenbutazone in 
dichloromethane (5 ~1) were applied as individual small spots on the 
base line of activated pre-coated Merck Silica gel 60 F254 cm plates. 
The plates were air dried, developed in ethyl acetate:benzene (1:4) 
solvent system, examined under ultra -violet light and the spots 
lightly outlined with a soft lead pencil. Individual plates were 
then sprayed with the spray systems A to Q (Table 14) and the colour 
reactions noted. The results are shown in Table 15 . 
The colour reactions with spray systems G, Hand J were similar to 
those reported by Awang (2), Bakke (4) and Beckstead (6) respectively 
and confirmed their findings. 
I 
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Table 15 COLOUR REACTIONS WITH SPRAY SYSTEMS LISTED IN 
Table 14 
Spray Colour reaction 
Phenylbutazone Oxyphenbutazone 
A No visible colour No visible colour reaction reaction 
B Blue stippled Blue stippled 
, 
C Pink yellow Yellow 
D Yellow Yellow 
E Brown yellow Pal e yell ow 
F Brown Yellow 
G Yellow orange Yellow 
H Green gray Yellow 
I Yell ow Yellow 
J Pale yellow on Pale yellow standi ng 
K No colour No colour 
L Pale yellow Pale yellow 
M Pal e yellow Pale yellow 
N No colour No co lour 
0 Ye 11 ow Yellow 
P Purple brown Yellow 
Q Pale lemon Purple 
74 
Spray system H gave the best colour differentiation between phenyl= 
butazone and oxyphenbutazone. It was also found to give effective 
colour reactions with other possible metabolites and decomposition 
products of phenylbutazone as shown in Table 16. 
Table 16 COLOUR REACTIONS OF PHENYLBUTAZONE AND SOME OF ITS 
METABOLITES AND DECOMPOSITION PRODUCTS 
Phenylbutazone 
Oxyphenbutazone 
y-Hydroxy (ring lactone form) derivative 
y-Hydroxy (straight chain hydroxyl form) 
derivative 
4-Hydroxy deri va ti ve 
p-Y-Dihydroxy derivative 
p-4-Hydroxy derivative 
green grey 
yellow 
purple 
orange brown 
green grey 
yellow 
yellow 
This spray system was therefore used in all subsequent experiments 
unless otherwise stated. The method consisted of spraying the 
plate evenly with finely atomised spray reagent H, heating at 10SoC 
for three minutes and noting the colour formed . 
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3. CHROMATOGRAPHIC PLATES USED FOR TLC 
3.1 Evaluation of Chromatographic Plates Used for TLC 
Table 17 lists the TLC plates of 0,25 mm layer thickness that 
were tested. 
Table 17 TLC PLATES TESTED FOR SEPARATION AND AUTORADIO= 
GRAPHY OF PHENYLBUTAZONE, ITS METABOLITES . AND 
DECOMPOSITION PRODUCTS 
1 Laboratory prepared Alumina G plate 
2 Laboratory prepared Sil i ca gel GF254 plate 
3 Laboratory prepared Si lica gel GF254 in Bismuth nitrate 
solution (m Bi (N03)3 = 0,05 mol.kg -
1) in 1,5% nitric acid 
4 Prepafed Cherrie Erzeugnis se AG DSF A plate 
5 Pre-coated Merck Si lica gel 60 F254 plates 
.One per cent solutions of phe nylbutazone, oxyphenbutazone and 
the y-hydroxy derivative (ring lactone form) in dichloromethane 
and the extract of the uri ne fro m a rat dosed with phenylbutazone 
were spotted on each of the plates listed in Table 17. The 
plates were dried, developed and sprayed. 
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The results showed that there was considerable streaking 
between the spots on the Alumina G plate and only the strongly 
non-polar compounds were 'moved from the origin. Separation 
was efficient on both the laboratory prepared Silica gel plates 
and the Cherrie Erzeugnisse plates, but results were found to 
vary; also the plates powdered, a property which made them 
unsuitable for autoradiography. These experiments showed that 
only pre-coated Merck Silica gel 60 F254 plates were suitable 
for autoradiography, therefore these plates were used for all 
subsequent thin layer chromatography, unless otherwise stated. 
3.2 Preparation of Preparative Plates 
Slurries of Silica gel 60 PF254 (Merck) were prepared in 10% 
sodium thiosulphate solution to determine the optimum quantities 
required to prepare 5 plates of 0,55 mm layer thickness. 
These optimum quantities were found to be 60 g of Silica gel in 
150 ml of 10% sodium thiosulphate solution. It was found that 
10% sodium thiosulphate inhibits on-plate oxidation during the 
long development process used on preparative plates. (vide 5.3.2) 
4. EVALUATION OF SOLVENT SYSTEMS 
The solvent systems listed in Table 18 were investigated to determine 
the most effective method of separating phenylbutazone, its decompo= 
sition products and possible metabolites. 
Table 18 
I 
II 
III 
IV 
V 
VI 
VII 
VII I 
IX 
X 
XI 
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SOLVENT SYSTEMS TESTED FOR THE SEPARATION OF PHENYL= 
BUTAZONE, ITS OECOMPOSITION PRODUCTS AND POSSIBLE 
METABOLITES 
Parts by volume 
Ethyl acetate 85 
Methanol 10 
Ammonia 25% 5 
Cyclohexane 60 
Chloroform 30 
Methanol 5 
Glacial acetic acid 5 
Ch 1 oroform 10 
Ethanol 1 
Ethyl acetate 1 
Benzene 4 
Dichloromethane 9 
Acetone 1 
Butanol 4 
Acetic acid 1 
Water 1 
Chloroform 10 
Ethano 1 0,5 
Ch 1 oroform 10 . 
Ethanol 0,25 
Ch 1 oroform 9,5 
Ethanol 0,5 
Chloroform 10 
Ethanol 0,1 
Cyclohexane 60 
Ch 1 oroform 30 
Methanol 4 
Acetic acid 4 
Acetone 2 
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Table 18 (continued) 
Cyclohexane 60 
Ch 1 oroform 30 
XII Methanol 5 
Acetic ai;id 4 
Acetone 1 
XIII Di ch 1 oromethane 10 Acetone 3 
XIV Dichloromethane 9 Acetone 1,5 
Ch 1 oroform 9 
XV Benzene 8 
Methanol 1 
Cyclohexane 9 
XVI Dichloromethane 8 
Acetone 3 
XVII Chloroform 10 Ethano 1 1,5 
XVIII Ch 1 oroform 10 Ethanol 2 
XVIX Acetone 7 Ch 1 oroform 3 
XX Acetone 8 Chloroform 3 
XXI Acetone 7 Chloroform 4 
XXII Acetone 6 Methano 1 4 
XXIII Dichloromethane 5 Acetone 2 
Butanol 5 
XXIV Methanol 1 Acetic acid 3,6 
Water 0,8 
Butanol 4 
XXV Acetic acid 1 
Water 0,5 
79 
Table 18 (continued) 
(a) Chloroform 4 
Acetone 1 
XXVI fo 11 owed in the same direction by 
(b) Heptane 55 
Acetone 35 
Chloroform 30 
Acetic acid 1 
(a) Cyclohexane 60 
Chloroform 30 
Methanol 5 
Acetic acid 5 
XXVII foll owed at right 
angles by 
(b) Chloroform 7 
Acetone 2 
Methanol 1 
4.1 Preliminary Tests with Solvent Systems to Separate Phenyl= 
butazone and Low Polarity Metabolites and Decomposition 
Products 
4.1.1 Separation of Phenylbutazone and Oxyphenbutazone 
As can be seen from the Rf values given in Table 19 
solvent system IV separated Phenylbutazone from 
Oxyphenbutazone most effectively and also moved the 
compounds to an intermediate position on the plate 
between the origin and solvent front. 
Table 19 
Phenylbutazone 
Oxyphenbutazone 
4.1. 2 
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~f VALUES OF PHENYLBUTAZONE AND OXYPHENBUTAZONE IN 
SOLVENT SYSTEMS I TO VI 
+ II III IV V VI 
0,84 0,4 0,93 0,83 0,87 Too polar 
incomplete 0,17 0,73 0,43 0,5 Too polar 
. separation 
Unless otherwise stated, this solvent system was 
selected for use in subsequent tests involving these 
two substances in TLC examinations, provided no 
other compounds were present. 
Choice of Reference Standard 
Experiments showed that there were variations in 
the Rf values of individual substances from one 
experiment to another and for this reason it seemed 
advisable to refer all Rf values to a suitable 
standard. Oxyphenbutazone was chosen as the 
reference standard and given an Rf value of 1. 
Relative Rf values quoted hereafter are related to 
this standard. 
Table ZO 
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4.1.3 Separation Gif Phenylbutazone, Its y-Hydroxy (Ring 
Lactone Form) and 4-Hydroxy Derivatives and Oxyphen= 
butazone 
One per cent solutions of the compounds in dichloro= 
methane {5 ~l) were spotted on plates prepared from 
Silica gel GFZ54 slurry in McIlvaine buffer as 
recommended by Awan9 (Z), the plates dried, developed 
in solvent systems II, III, VII and VIII, and 
sprayed. The relative Rf values are shown in 
Table ZO. 
RELATIVE Rf VALUES OF PHENYLBUTAZONE, ITS y-HYDROXY 
(RING LACTONE FORM) AND 4-HYDROXY DERIVATIVES 
Solvent System Phenylbutazone y-Hydroxy Derivative 4-Hydroxy (Ring Lactone Form) Derivative 
II 1,96 1,1 1,16 
III 1,09 1,03 1,07 
VII 2,05 1,38 1,15 
. 
VIII 2,18 1,79 1,21 
As can be seen from Table 20 trese solvent systems, 
with the exception of III, separated phenylbutazone 
from its deri vatives. However, the 2 derivatives 
were not well separated from each other. 
I 
I 
I 
Table 21 
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4.1.4 Separation of the y-Hydroxy (Ring Lactone Form) and 
4-Hydroxy Derivatives of Phenylbutazone and Oxyphen= · 
butazone 
Relative Rf values, using solvent systems IX to XVI 
are shown in Table 21. 
RELATIVE Rf VALUES OF THE y-HYDROXY (RING LACTONE FORM) 
AND 4-HYDROXY DERIVATIVES OF PHENYLBUTAZONE 
Solvent System y-Hydroxy Derivative 4-Hydroxy Derivative (Ring Lactone Form) 
IX 
X 
XI 
XII 
XI II 
XIV 
XV 
XVI 
1,33 1,16 
1,86 1,31 
1,81 1,38 
1,53 1,39 
1,17 1,10 
1,19 1,15 
1,81 1,41 
1,15 1,27 
It can be seen that solvent systems X and XV sepa= 
rated the metabolites adequately. The actual Rf 
values obtained with these two solvent systems 
show that solvent system XV eluted these metabo= 
lites to approximately midway between the origin 
and the solvent front, and was therefore selected 
Table 22 
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for all subsequent work for the separation of 
these compounds. (Table 22) 
~f VALUES OF THE Y-HYDROXY (RING LACTONE FORM) AND 4-
HYDROXY DERIVATIVES OF PHENYLBUTAZONE AND OXYPHENBUTA= 
ZONE 
Solvent System Y-Hydroxy Derivative 4-Hydroxy Oxyphenbutazone (Ring Lactone Form) Derivative 
X 0,48 0,29 0,11 
XV 0,58 0,44 0,32 
4.2 Preliminary Tests with Solvent Systems to Separate Oxyphen= 
butazone and the More Polar Metabolites and Decomposition 
Products of Phenylbutazone 
4.2.1 Separation of Oxyphenbutazone and the Y-hydroxy 
(Straight Chain Hydroxyl Form) and p-Y-Dihydroxy 
Derivatives of Phenylbutazone 
The Rf and relative Rf values obtained using various 
solvent systems are shown in Table 23. 
As can be seen from this Table the most effective 
solvent systems for the separation of these com= 
Table 23 
Solvent 
System 
III 
VII 
VII I 
XVI I 
XVI II 
XIX 
XX 
XXI 
XXII 
XXII I 
XXIV 
XXV 
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~f AND RELATIVE Rf VALUES OF OXYPHENBUTAZONE AND THE 
MORE POLAR METABOLITES OF PHENYLBUTAZONE 
Oxyphenbutazone Y-Hydroxy Derivative p-Y-Dihydroxy (Straight Chain Form) Derivative 
Rf 
0,53 
0,49 
0,39 
0,54 
0,52 
0,43 
0,50 
0,44 
0,40 
0,38 
Relative Rf 
Relative Rf 
Relative 
Rf Rf Rf 
1,00 0,32 0,55 0,15 0,29 
1,00 0,13 0,27 0,07 0,15 
1,00 0,08 0,22 0,03 0,07 
1,00 0,32 0,58 0,15 0,27 
1,00 0,24 0,46 0,12 0,22 
1,00 0,28 0,65 0,06 0,01 
1,00 0,32 0,64 0,07 . 0,01 
1,00 0,25 0,57 0,04 0,009 
1,00 0,36 0,57 0,08 0,18 
1,00 a ,OS 0,012 0,00 0,00 
N a C LEA R R E S U L T S 
N a C LEA R RES U L T S 
pounds are the chloroform:ethanol solvent systems 
III and XVII. Experiments using multiple develop= 
ments with either the same or different solvent 
systems showed that i t was possible to effect a 
slightly better separation, but this advantage was 
outweighed by the effects of on-plate oxidation. 
4.2.2 
i ) 
i i ) 
85 
Assessment of Solvent Systems Using Extracts of 
Urine from Rats Dosed with Phenylbutazone 
As a result of these preliminary tests the follow= 
ing tests were undertaken with extracts of rat 
urine obtained by the recommended extraction 
procedure outlined in the following chapter. 
Three plates, numbered (a) , (b) and (c) were pre= 
pared by applying small spots of the following 
solutions on the origin, 1 cm apart. 
Extract of urine from an untreated rat. 
Extract of ur·i ne from an untreated rat + a solu= 
tion of oxyphenbutazone. 
iii) Extract of urine from a rat dosed with phenyl= 
butazone. 
iv) One per cent solution of oxyphenbutazone in 
dichloromethane . 
Immediately after the spots had drieg Plate (a) 
was developed in solvent system XVII, Plate (b) 
in solvent system III and P.late (c) in solvent 
system XXV, to a solvent front 15 cm from the 
origin. They were then dried and sprayed. 
As can be seen from Figure 39 solvent system III 
moved the Y-hydroxy (straight chain hydroxyl form) 
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Fig. 39 Chromatograms Showing separation of Polar Metabolites of 
Phenylbutazone in the Extract of Rat Urine 
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derivative, recognised by its orange "brown colour, 
well above the origin (Rf value 0,41) and separated 
oxyphenbutazone and its metabolites or decomposition 
products. Solvent system XVII also moved the 
Y-hydroxy (straight chain hydroxyl form) derivative 
well above the origin (Rf value 0,42) but did not 
separate oxyphenbutazone and its metabolites or 
decomposition products. Solvent system XXV lifted 
all the material from the origin and separated the 
highly polar metabolites. 
4.3 Solvent Systems Selected for Chromatographic Separations 
On the basis of this preliminary experimental work it was 
decided to use the following solvent systems for chromato= 
graphic separations unless otherwise stated: 
(a) Separation of phenylbutazone from its Y-hydroxy (ring lac= 
tone form) and 4-hydroxy derivatives and oxyphenbutazone: 
Solvent System xv. 
(b) Separation of oxyphenbutazone , i ts metabolites and decompo= 
sition products and the Y-hydroxy (straight chain hydroxyl 
form) and p-Y-dihydroxy derivatives of phenylbutazone: 
Solvent System III. 
(c) Separation of highly polar substances (probably conjugates): 
Solvent System xxv 
·Tab1e 24 
Sol vent 
XV 
III 
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Table 24 lists thE! Rf values of phenylbutazone and its 
possible metabolites in two of the above solvent systems. 
RELATIVE Rf VALUES OF PHENYLBUTAZONE AND ITS POSSIBLE 
METABOLI TES 
Substance Relative Rf Value 
Phenylbutazone 2,00 
Y -Hydroxy deri vati ve (ri ng 1 actone form) .of PB 1,81 
4-Hydroxy derivative of phenylbutazone 1,41 
4-Hydroxy derivative of oxyphenbutazone 0,80 
Y-Hydroxy (straight chain hydroxyl form) of PB 0,55 
p-Y-Dihydroxy derivative of phenylbutazone 0,31 
5. DECOMPOSITION OF PHENYLBUTAZONE AND OXYPHENBUTAZONE 
Experiments were conducted to establish the extent of decomposition 
of phenylbutazone and oxyphenbutazone in solution, as well as during 
on-plate oxidation in TLC procedures, and methods which would either 
minimise or prevent such decomposition were assessed. Throughout 
these experiments solvent system IV was used to elute the drugs. 
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5.1 Decomposition of Phenylbutazone and Oxyphenbutazone in 
Aqueous Solution 
Samples of 1% solutions of the drugs in sodium hydroxide 
solution (m NaOH = 0,1 mol.kg-
I ) were allowed to stand in 
uncovered beakers for 3 days, acidified with hydrochloric 
acid and extracted with dichloromethane. The dichloro= 
methane extract was spotted on activated 5 x 5 cm plates, 
the plates developed for 3 cm, dried, examined under ultra= 
violet light and sprayed. 
Freshly prepared solutions in dichloromethane were ' immedia= 
tely spotted on plates and treated similarly to act as 
controls. No evidence was found that either drug had 
decomposed on standing in solution over a period of 3 days 
in the form of its sodium salt . 
5.2 Decomposition of Phenylbutazone and Oxyphenbutazone on 
TLC Plates 
One per cent solutions of the drugs in dichloromethane were 
spotted on activated 5 x 5 cm plates and the plates allowed 
to stand in the air for 24 h. Freshly prepared solutions 
were then spotted on these plates, which were immediately 
developed for 3 cm, examined under ultraviolet light and 
sprayed. In order to clarify the interpretation of the 
Table 25 
Relative 
butazone 
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chromatogram the spot produced by the applied drug was 
given an Rf value of 1 and the Rf values of the decomposi= 
tion products calculated relative to this. 
It was found that freshly prepared solutions which were 
developed immediately underwent no decomposition, whereas 
the 24 h samples were completely decomposed into a major 
product and minor products as indicated by Table 25. 
~f Values of On-plate Degradation Products of Phenyl= 
butazone and Oxyphenbutazone 
Rf Values of Phenyl= Relative Rf Values of Oxyphen= 
Decomposition Products butazone Decomposition Products 
0,77 (mi nor spot) 0,31 (minor spot) 
0,06 (major spot) 0,2 (minor spot) 
0,0 . (major spot) 
5.3 Prevention of On-plate Oxidation of Phenylbutazone and 
Some of Its Metabolites 
The following experiments were carried out to ascertain 
whether it was possible to prevent or reduce on-plate 
oxidation. 
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5.3.1 Incorporat1on of McIlvaine Buffer 
5.3.2 
Test plates were prepared from Silica gel GF254 
(20 parts), Silica gel G (20 parts) in McIlvaine 
Buffer (80 parts). McIlvaine buffer was prepared 
by. adding 37 ml of citric acid solution 
(mcitric 
solution 
acid = 0,1 mol.kg-1) to 63 ml disodium phosphate 
-1) (mNa2HP04 = 0,2 mol·kg (2). 
Pre-coated Merck Silica gel 60 F254 plates were 
used as control plates. 
So 1 vent II was used as it vias reported to be 
effective in separating phenylbutazone and its 
decomposition products (6). Five microlitres of 
a 1% solution of phenylbutazone in dichloromethane 
was spotted on the test and control plates at 
15 min intervals over a period of 60 min, the 
plates dried, developed and sprayed. Figure 40 
shows that decomposition started within 15 min and 
the inclusion of McIlvaine buffer gave a minimal 
degree of protection. 
Incorporation of 10% Sodium Thiosulphate·Sblution (22) 
A 20 x 20 cm test plate was prepared from a slurry 
containing 1 part Merck Silica gel PF254 in 2 parts 
10% sodium thiosulphate solution (Plate 1) and 
Fig. 
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Compari son of Decompos ition with Time of Phenylbutazone 
on Two Different Plates 
and another 20 x 20 cm plate was prepared using 
water as the vehicle to act as a control (Plate 2). 
Five microlitres each of 1% solutions of phenyl= 
butazone, oxyphenbutazone and the ,Y-hydroxy (ring 
lactone form) derivative of phenylbutazone in 
dichloromethane were spotted on the plates 3 times 
at 30 min intervals . 
Using solvent system XXVI, which included solvents 
(a) and (b) , plates 1 and 2 were developed in 
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solvent (a), the plates dried and developed in the 
same direction in solvent (b). The plates were 
examined under ultraviolet light and the spots 
marked. The spray reagent was not used as sodium 
thiosulphate was found to interfere with its 
action. 
Figure 41 shows, firstly, that a product of decom= 
position of phenylbutazone was present in plate 2 
after 60 min exposure to air, but was not present 
in plate 1; secondly, that the size of the spots 
(indicative of concentration), of the decomposition 
products of oxyphenbutazone increased with time in 
plate 2, but not in plate 1, and thirdly, there 
did not appear to be any difference in the decom= 
position of the Y-hydroxy (ring lactone form) in 
plates 1 and 2. Evidently it equilibrated with 
its straight chain hydroxyl form and formed a 
decomposition product to the same extent in both 
plates. 
The results of these tests indicated that the 
degree of protection from decomposition given by 
McIlvaine buffer did not warrant its use. 
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CHAPTER VIII 
PREPARATION OF SAMPLES FROM THE RAT 
1. COLLECTION OF SAMPLES 
Aft~r dosing, the rat was placed in a Metabowl whereby the faeces and 
urine could be collected separately. The contamination of excreta 
was a serious problem when rat cubes were used as food and the many 
methods tried to overcome this problem proved unsatisfactory. A 
liquid food consisting of glucose/electrolyte mixture was introduced 
into the drinking container and this arrangement resolved the contami= 
nation problem, and at the same time gave the rat adequate nourishment. 
However, the 48 h volume of urine increased from 15 - 20 ml to over 
70 ml. This, in turn, affected the efficiency of the extraction 
methods, and, therefore, in experiments intended for the quantitative 
determination of metabolites in specimens excreted over a period of 
48 h, rats were provided with drinking water, but were given no solid 
or liquid food. 
1.1 Prevention of Decomposition of Metabolites During Collection 
Time 
It was found that the decomposition of metabolites could be 
reduced to a minimum by collecting the excretion products 
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at a low temperature . To accomplish this, the collecting 
vessels of the Metabowl were placed in methanol at -200 C. 
Great care had to be taken to ensure that the urine did not 
freeze in the tubes leading to the collecting vessels and on 
subsequent melting overflow into the faeces collecting 
flask. This problem was overcome by blowing warm air on to 
the glass connections leading to the collection vessel. 
2. EXAMINATION OF URINARY PRODUCTS 
2.1 Preliminary Procedures Tested for the Extraction of 
Metabolites from Urine of Rats with Organic Solvents 
Many methods were tried for the extraction of metabolites 
from samples of urine with organic solvents. Two solvents 
showed promise. dichloromethane and dichloroethane. Dichloro= 
methane has a lower boiling point, which is an advantage in 
that the time of evaporation decreases, thus reducing the 
possibility of decomposition of metabolites during the 
extraction process. 
Well known methods used to improve the extraction process, 
such as salting out wi th ammon i um sulphate, gave little 
advantage. Different ext raction procedures were also tried . 
In certain cases a small quantity of solvent was used and 
the contents well mixed in a nipple tube on a vortex shaker. 
"- .. 
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In others, a larger proportion of solvent was added and 
shaken with urine on a mechanical shaker. The latter 
method appeared to g'ive more quantitative extraction. 
~, 
The 1 extraction processes, finally selected, were as 
follows: 
2.1.1 
2.1. 2 
Volumes of 5 ml and less 
Dichloromethane (15 ml) was added to urine (5 ml), 
the mixture was acidified to pH 1-3 with sulphuric 
acid and shaken in a rotary shaker for 20 min before 
centrifuging at 3 000 r.p.m. for 10 min. The 
solvent layer was pipetted off and the extraction 
repeated twice using further 15 ml of dichloro= 
methane. The volume of the combined extracts was 
reduced to about 0,3 ml under nitrogen . 
Volumes Between 5 and 40 ml 
A volume of dichloromethane equal to half the 
volume of urine to be extracted was added to the 
urine, the mixture acidified with sulphuric acid 
to pH 1-3 and shaken for 5 min. The solvent 
layers were separated by centrifuging at 3 000 
r.p.m. for 15 min and the organic layer removed. 
The urine was extracted with further volumes of 
so 1 vent until extracti on was complete. Th e 
2.1.3 
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solvent extracts were mixed and the volume reduced 
by evaporation under nitrogen at 450 C. 
Estimation of the Number of Extractions Required to 
Obtain Complete Extraction of Metabolites from the 
Urine of Rats Dosed with Phenylbutazone 
(a) TLC Procedure 
Samples of urine from 3 rats dosed with phenylbuta= 
zone were extracted by method 2.1 .1. After each 
extraction a 5 x 5 cm TLC plate was spotted with 
the extract, dried, developed and sprayed . 
In two samples, it was found that extraction was 
complete after six extractions and in the third 
sample, after five extractions. 
(b) Liquid Scinti llation Counting Procedure 
Samples from 2 rats treated with 14C labelled 
phenylbutazone (s.a. 10,84 KBq-mg- 1) were 
extracted by method 2.1.2 and after each extrac= 
tion 10 vl was mixed with 10 ml of scintillant 
and counted . 
As can be seen from Table 26 , it was found that, 
after 5 extractions, the count was low and steady. 
Table 26 
Extract 
1st - 3rd 
4th 
5th 
6th 
·2.1.4 
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RADIOACTIVITY, MEASURED IN CPM, OF EXTRACTS OF URINE 
FROM RATS DOSED WITH 14C PHENYLBUTAZONE 
Rat No.1 Rat No. 2 
Not counted Not counted 
355 348 
141 152 
150 140 
These results indicated that at least five extrac= 
tions should be undertaken to ensure near complete 
extraction of the metabolites from the urine of 
rats dosed with phenylbutazone . 
Test . for Decomposition of Phenylbutazone and 
Oxyphenbutazone During Extraction Process 
Phenylbutazone and oxyphenbutazone (1 mg of each) 
were added to separate 5 ml quantities of urine 
from an untreated rat . These urine samples were 
then extracted using method 2.1 . 1, and the extracts 
spotted on to TLC plates. Separate spots of 5 ~l 
of freshly prepared solutions of phenylbutazone and 
oxyphenbutazone in dichloromethane were also applied 
to the plates which were then developed and sprayed. 
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It was found that both the phenylbutazone and oxy= 
phenbutazone, after extraction, produced a spot 
due to a decomposition product which was barely 
visible, and thus indicated that decomposition 
during extraction was insignificant provided the 
extraction process was carried out rapidly. 
2.2 Establishment of Time After Dosing for First Collection of 
Urine from Rats Dosed with Phenylbutazone 
Samples of 0 - 6 h urine and 6 - 24 h urine from a rat dosed 
with phenylbutazone and a sample of urine from an untreated 
rat were collected. Five millilitres of each of these 
samples was extracted by method 2.1.1 and spotted onto a 
5 x 5 cm TLC plate which was dried, developed and sprayed. 
As can be seen from Figure 42 the 24 h urine contained more 
m~tabolites than the 6 h urine, and these were present in 
higher concentrations. 
These results indicated that 6 h urine samples give an in= 
complete picture of metabolism of phenylbutazone in rats, 
and consequently for these studies urine samples should 
not be taken less than 24 h after dosing. 
Fi g. 42 
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i extract of urine from an 
untreated rat 
0 i i extract of 0-6 h urine • from a treated rat 0 
'"' 
A ~ iii extract of 6-24 h urine 
i i iii from a treated rat 
Chromatogram of the Extracts of 0 - 6 hand 6 - 24 h Urine 
Samples from a Rat Dosed with Phenylbutazone Together with 
Control 
2.3 Determination of the Effect of Variations in the Dose on the 
Metabolism of Phenylbutazone 
Two 
and 
rats were dosed with phenylbutazone, 
the other with 50 mg_kg- 1, and urine 
one with 12 mg_kg- 1 
samples collected 
after 24 h. About the same volume of urine was produced 
in each case. 
Samples of urine (5 ml) were extracted by method 2.1.1 and 
5 ).11 of each extract was spotted on to TLC pl ates, whi ch 
were dried, developed and sprayed. 
There was no apparent di ffe rence in the number and size of 
spots produced in each case, showing that differences in 
dosage at this level did not alter the pattern of excretion 
in 24 h urine. 
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2.4 Extraction of Water Soluble Metabolites from the Urine of 
Rats Dosed with Phenylbutazone 
2.4.1 Test for Hydrolysable Conjugates in Urine 
Initially the activity of the a-glucuronidase/ 
aryl sulfatase (Boehri nger /Mannhe;",) enzyme was 
established as follows: 
Twenty milligram of the chemically stable cinchoni= 
dine complex of phenolphthalein gluc ~ronide was 
treated with 0,5 ml hydrochloric acid (mHCl = 
2 mo 1 . kg -1) . Th is 1 eft the phenol phtha 1 Eii'n 
gluc~ ronide as a st ic ky precipitate and formed the 
soluble cinchonidine hydrochloride. Ethyl acetate 
(1 ml) was added, the mixture shaken, separated 
and the ethyl acetate fraction passed through a 
cottonwool plug. This extraction was repeated 
6 ti mes, the ethyl acetate fractions mi xed and _ 
evaporated under nitrogen to yield a colourless 
sticky residue , which was dissolved in 0,5 ml 
-warm distilled water. The pH was adjusted to 
5,0 with sodium hydroxide solution (m NaOH = 
0,1 mol .kg-1), the volume made up to 1,25 ml with 
distilled water and the solution clarified by 
adding charcoal and filtering. A portion of this 
phenolphthalein gluc~ronide solution (0,1 ml) was 
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mixed with 0,9 ml of S-glu~ronidase/sulfatase 
in acetate buffer of pH 4,5 and incubated at 370 C 
for 45 min. A second portion of phenolphthalein 
gluc~ronide solution (0,1 ml) in acetate buffer 
(pH 4,5) to which no S-gluc~ronida~ulfatase was 
added was similarly incubated to act as a control. 
At the end of the 
.solution (mNaOH = 
tubes. 
experiment sodium hydroxide 
-1 0,1 mol·kg ) was added to both 
A pink colour was produced in the test solution and 
not in the control, indicating that the enzyme was 
active and had hydrolysed the gluc~onide leaving 
the phenolphthalein to act as an indicator. 
This active enzyme was used to ascertain whether 
samples of urine from rats dosed with phenylbuta= 
zone contained O-gluc(~ronide or O-sulphate conju= 
gates as follows : 
Urine (5 ml) from a rat dosed with 14C phenylbu= 
tazorie was extracted according to method 2.1.1 and 
10 ~l spotted onto a pre-coated Merck 5 x 5 cm TLC 
plate (spot i). The aqueous residue (1 ml) was 
then incubated with 0,1 ml S-gluc~ronidase/ 
sulfatase and 0,9 ml acetate buffer (pH 4,5) at 
1-
2.4.2 
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370 C for 3 h. Ten microlitres of the hydrolysate 
was spotted on the TLC plate (spot ii) and 1,2 ml 
dichloromethane used to extract the remainder. 
Ten microlitres of this extract was spotted on the 
plate (spot iii). A.t the same time oxyphenbuta= 
zone was added to urine from an untreated rat and 
5 ml of the urine extracted by method 2.1.1. Ten 
microl itres of the extract was spotted onto the 
plate (spot iv). The plate was dried, developed 
in solvent system XV and sprayed. 
Figure 43 shows that urine, after treatment with 
8-gluc~ronidase/sulfatase, gives a major spot 
corresponding to the 4-hydroxyl derivative of 
oxyphenbutazone which could either be an artifact 
due to decomposition of oxyphenbutazone during the 
incubation period, or an authentic product of 
metabolism. A minor spot corresponding to oxy= 
phenbutazone was also evident. 
Test for Water Soluble, Non-hydrolysable Compounds 
in Urine 
After extraction with dichloromethane of the incu= 
bation mixture, as described in 2.4.1, 0,5 ml of 
the aqueous layer was mixed with 10 ml aquagel and 
counted in a scintillation spectrometer. The 
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result indi cated that non-hydrolysable compounds 
accounted for about 14% of the water soluble meta= 
bol ites. 
A further portion of the aqueous layer (10 ~l), as 
described above, was also spotted on a TLC plate 
prepared with sodium thiosulphate, the plate dried, 
developed in solvent system XXVII and examined 
under ultraviolet light. Spots were visible which 
caul d be due' to metabo 1 i tes, but it was not pass i b 1 e 
to identify them. 
2.5 Assessment of the Degree of Decomposition of Phenylbutazone, 
Its Y-hydroxy Derivative and Oxyphenbutazone in Urine 
During a 24 h Incubation Period at 37 0 C 
This experiment was carried out to assess whether possib'le 
decomposition of the metabolites could take place in the 
rat's bladder,. Freshly collected urine (5 ml) from un= 
treated rats was placed in each of 4 test tubes and the 
following substances added : 
tube i 
tube ii 
tube iii -
tube iv 
1 mg phenylbutazone 
1 mg oxyphenbutazone 
1 mg Y- hydroxy derivative of phenylbutazone 
nil (control) 
~ green grey 
~ violet 
Solvent system XV 
o 
• 
o , 
o 
, D e 0 
O! 0 0 
C OPB PB Y·OH PB 
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o yellow r:;;:::::J vis.ible under Gil UV light only . 
lID orange brown C Control 
Solvent system ttl 
o 
o 
o 
• 
4P 
fJ 0 () B 
C OPB PB Y·OH PB 
Fig. 44 Chromatogram of Extracted Rat Urine after Incubation at 
370 C with Phenylbutazone, its Y-hydroxy Derivative and 
Oxyphenbutazone 
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The tubes were incubated at 370 C for 24 h, extracted ac= 
cording to method 2. 1.1, spotted on 2 TLC plates, the plates 
dried, developed in solvent systems XV and III and sprayed. 
Figure 44 shows the degree of decomposition of each 
substance. 
These results indicate that phenylbutazone gave rise to one 
minor decomposition product, oxyphenbutazone to two decom= 
position products, and the Y-OH derivative an equilibration 
mixture of the ring lactone and the straight chain hydroxyl 
forms, and a minor decomposition product. As it is un= 
likely that the urine would remain in the bladder for as 
long as 24 h possible decomposit ion of phenylbutazone and 
its Y-OH derivative appeared to be of little significance. 
However, the results showed that oxyphenbutazone had a 
much faster rate of decompos ition, therefore the presence 
of these additional spots in chromatograms of the urine 
could be either true products of metabolism or decomposi= 
tion products formed during excretion . 
3. EXAMINATION OF FAECES 
3.1 Measurement of Radioactiv ity in Faeces from Rats Dosed 
with 14C Labelled Phenylbutazone 
Lack of reproducibility was the cause of possible error in the 
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measurement of radioactivity in the faeces of rats dosed 
with 14C labelled phenylbutazone. This was due to the 
difficulty of forming an homogenous sample, and quenching 
produced by the colour of the faeces. For these reasons 
various methods to digest and bleach samples of faeces were 
tried in order to produce an homogenous, colourless product 
which would give maximal counting efficiency. 
The best conditions for counting were obtained by using the 
following method: 
To 24 h faeces 60% perchloric acid (15 ml) was added and 
the mixture allowed to stand for 3 h before homogenisation. 
A measured volume of 0,5 to 1 ml of this homogenate was 
bleached by alkalising the mixture with 40% sodium hydroxide, 
warming and then adding 5 drops of 100 volume hydrogen 
peroxide. The mixture was boiled for 5 min, care being 
taken to avoid loss from effervescence. It was then 
carefully adjusted to pH 7 wi th concentrated hydrochl ori c 
aci d. 
This method produced a bleached, well homogenised sample 
which showed little quenching when measured for radioacti= 
vity in the liquid scintillation spectrometer. 
, 
3.2 
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Extraction of Metab~lites Present in the Faeces from Rats 
Dosed with 14 C Phenylbutazone 
A 24 h specimen of f '" ces (3 g) from a rat treated with 
14C phenylbutazone was homogenised in 15 ml of distilled 
water, centrifuged at 3 000 r . p.m.for 15 min and the 
mixture filtered. The filtrate was transferred to a round 
bottomed flask and freeze-dried overnight. It was re-
constituted in 3 ml acetate buffer (pH 4,5) and examined 
for the presence of hydrolysable and non-hydrolysable con= 
jugates by the methods used for examining urine. 
CHAPTER IX 
SYNTHESIS, ASSESSMENT OF PURITY AND PREPARATION 
OF CALIBRATION CURVES OF REFERENCE STANDARDS 
1. PHENYLBUTAZONE 
1.1 Confirmation of Relative Chromatographic Purity 
Solutions of phenylbutazone and oxyphenbutazone were 
freshly prepared in dichloromethane, spotted on five 
5 x 20 cm plates, dried, developed in the solvent systems 
listed in ,Table IB, examined under ultraviolet light, 
then sprayed and re-examined for coloured spots. 
Table 27 shows that in each case the solution of phenyl= 
butazone only prod uced one spot visible under ultraviolet 
light and after spraying. Thus it was assumed that the 
sample of phenylbutazone was chromatographically pure. 
1.2 Preparation of Calibration Curve. 
Solutions of phenylbutazone in chloroform:methanol (9:1) 
were prepared in dilutions ranging from 10 ~g.ml -l to 
-1 60 ~9·ml and the absorbance measured at 270 nm. The 
'results are shown in Table 28. 
Table 27 
Table 28 
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RELATIVE RfVALUES OF PHENYLBUTAZONE IN VARIOUS 
SOLVENTS 
Sol vents Relative Rf value 
XV 2,00 
III 1,26 
II 2,35 
XXVI (a) 1,17 
XXVI (b) 1,42 
ABSORBANCE OF SOLUTIONS OF PHENYLBUTAZONE IN 
CHLOROFORM:METHANOL (9:1) AT 270 nm 
Absorbance Di l ution (~g ml- 1) 
0,14 10 
0,26 20 
0,39 30 
0,51 40 
0,64 50 
0,76 60 
A graph (Figure 45) was prepared from these results. It con= 
forms to Beer-Lambert law . 
It 
0,80 
0,70 
0,60 
0,50 
0,40 
0,30 
0,20 
10 20 
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O,80r-----------------------,,-------. 
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0,30 
0,20 
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Phenylbutazone ~g'ml-1 
Fig, 45 Cal ibration Curves for Phenylbutazone and Oxyphenbutazone 
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2. PHENYLBUTAZONE LABELLED WITH 14C IN THE 4 POSITION 
14C Phenylbutazone was synthesised by Professor G E A Mathew using 
14 -1 2- C diethylmalonate (55,5 KBg : s .a. 1443 KBg- mg ) as the source 
of radioactivity. The method was as follows: 
The radiochemical in hexane was transferred to the reaction flask, 
·containing inactive diethyl malonate. The hexane was evaporated off 
using a nitrogen stream. 
N-butyl bromide, hydrazobenzene and sodium iodi de were added to the 
flask, the apparatus was flushed with nitrogen and the flask heated 
to 700 C with stirring of the reactants. A calculated volume of 
sodium ethoxide was added over 3 h and the mixture heated under 
reflux for 2 h. This procedure resulted in 1-butylation of di-ethyl 
malonate. 
To form the 3,5-dioxo-pyrazolidine ri ng the apparatus was then conver= 
ted to distillation and the ethanol slowly distilled off with gradual 
increase of temperature of the heating bath to 1200 C. The reaction 
mass set solid and the heating was continued at 1500 C for 2 h. 
The product was isolated by transferring the entire contents of the 
flask, using alternate portions of water (5 parts) and chloroform 
(1 part). into a separating funnel. The chloroform layer was re= 
moved and the aqueous layer extracted several times with chloroform 
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and once with ether before being run into a second 50 ml separating 
funne 1 • It was acidified with hydrochloric acid to pH 2 producing 
a yellow precipitate which was extracted several times with chloro= 
form. The extracts were combined and the solvent evaporated to 
1 eave the crude product, A. This crude product was dissolved in a 
minimum volume of chloroform and applied to a Pharmacia SR 25/100 
column packed with Mallinckrodt Silica AR CC4 (100 - 200 mesh). 
fractions were collected and analysed by TLC. 
The phenylbutazone fraction was collected until the emergence of a 
following coloured band and the solvent removed by rotary evapora= 
tion at 500 C leaving a white solid , B, which was dried under vacuum. 
Inactive phenylbutazone was added to B and low temperature crystal= 
lisation carried out from ether to give product C. 
The mother liquors were evaporated and more inactive phenylbutazone 
was added to the residue, D. 
from ether >gave product E. 
Low temperature recrystallisation 
C and E were dissolved in solvent wh ich was evaporated off leaving 
- 1 
a final product with a s . a. of 10,93 KBq -mg • 
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3. OXYPHENBUTAZONE 
3.1 Confirmation of Relative Chromatographic Purity 
A freshly prepBred solution of oxyphenbutazone in dichloro= 
methane was spotted on 2 pre-coated Merck 5 x 20 cm plates, 
the plates dried, developed in solvent systems III and XV, 
examined under ultraviolet light and sprayed. 
In addition to the major spot a small, weakly stained spot, 
with relative Rf values of 0,78 in solvent system III and 
0,59 in solvent system XV, was evident on both plates. 
This impurity was probably the 4-hydroxy derivative of 
oxyphenbutazone . In the light of these findings 
attempts were made to prepare a pure sample of oxyphen= 
butazone. 
3.2 Preparation of Pure Oxyphenbutazone 
Purification by re-crystallisation from ether-petroleum 
ether (B P 40-600 C) proved ineffective. It was therefore 
decided to use the following TLC technique to prepare a 
chromatographically pure solution of oxyphenbutazone. 
Oxyphenbutazone (100 mg) was dissolved in 2 ml of dichloro= 
methane and applied to a preparative plate of Silica gel 
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60 PF254 with the a'id of a chromatocharger. The plate was 
developed in solvent system III to a height of 15 cm and 
examined under ultraviolet light. A very wide band was 
visible with an Rf value in the region of 0,5, which was 
taken to be oxyphenbutazone, and a narrow band (Rf 0,41) 
wh i ch was consi dered to , be a de compos iti on product. 
In order to guard against contamination by the decomposition 
product, only the upper three-quarters of the top band was 
scraped off, eluted with 10 ml chloroform:methanol (9:1) and 
the eluate centrifuged. TLC, in solvent systems III and 
XV, showed no evidence of the sample containing impurities. 
To an aliquot of this solution (2,5 ml) chloroform:methanol 
(9:1) was added to form a 1:2 dilution (solution A). A 
sample of this solution (0,05 ml) was .diluted to form a 
1:2 000 dilution (solution 8) and 3 ml of solution 8 was 
transferred to a cuvette and the absorbance measured 
(0,125). This absorbance value was applied to the calibra= 
tion curve which showed that solution 8 had a concentration 
of 18 ~g ml- 1. Solution A was used in the quantitative 
procedure us i ng multi p 1 e inverse isotope dil uti on. 
3.3 Preparation of Calibration Curve 
As the crystalline sample supplied by Ciba Geigy showed an 
insignificant content of impurities, it was used for the 
Table 29 
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preparation of the Calibration Curve. 
Solutions of oxyphenbutazone in chloroform:methanol (9:1) 
were prepared in dilutions ranging from 10 to 50 ug ml- 1 
and the absorbance measured at 270 nm. A Cal ibration 
Curve was prepared (Figure 45) from the results shown in 
Table 29. 
ABSORBANCE OF SOLUTIONS OF OXYPHENBUTAZONE IN 
CHLOROFORM:METHANOL (9:1) AT 270 nm 
Absorbance Dilution (llg. m1 - 1, 
0,140 10 
0,285 20 
0,420 30 
0,555 40 
0,700 50 
4. Y-HYDROXY DERIVATIVE OF PHENYLBUTAZONE 
4. 1 Synthesis 
The y-OH derivative of phenylbutazone was synthesised in 
this laboratory according to the method of Denss (20) as 
v-Hydroxy phenylbutazone 
(straight chain hydroxyl form) 
1 
99 
HN--N 
. I 
o-c c-o 
o/~/ 
I I"H 
H3CHC, /CH2 
C 
H2 
y ~Hydroxypheny Ibutozone 
(ring lactone form) 
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y~(Ethy lened ioxy)- phenyl butazone 
p.toluene 
acetone 
or 
Raney Ni/H2 
sulphonic acid 1 
Y-Ketopheny Ibutazone 
Fig. 46 Synthesis of Y-Hydroxy Derivative of Phenylbutazone 
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shown in Figure 46. The ring lactone form was used in 
the experimental wot'k, as it remained pure in the crystal= 
line state. The melting point of this form was 1650 C. 
4.2 Confirmation of Relative Chromatographic Purity 
Table 30 
Freshly prepared solutions of the Y-hydroxy derivative of 
phenylbutazone and oxyphenbutazone were prepared in di= 
·chloromethane, spotted on 5 pre-coated Merck 5 x 20 cm 
plates, the plates dried and immediately developed in the 
solvent systems listed in Table 30. It was important to 
complete these steps in the shortest possible time to 
prevent formation of the straight chain hydoxyl form of the 
Y-hydroxy derivative. The plates were examined under 
ultraviolet light and then sprayed. Relative Rf values of 
the Y-hydroxy derivative in various solvents are shown in 
Table 30. 
RELATIVE Rf VALUES OF THE Y-HYDROXY DERIVATIVE OF 
PHENYLBUTAZONE 
Solvents Relative Rf values 
XV 1,80 
III 1,17 
X 1,86 
II 1,05 
XXVI (a) 1,15 
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The solution of the Y-hydroxy derivative of phenylbutazone 
produced only one spot visible under ultraviolet light and 
after spraying, thus it was assumed that the sample was 
chromatographically pure. 
4.3 Preparation of a Calibration Curve 
Table 31 
Solutions of the Y-hydroxy derivative of phenylbutazone in 
chloroform:methanol (9:1) were prepared in dilutions ranging 
from 5 to 40 Ilg'ml-1, and their absorbance measured at 
270 nm. 
A Calibration Curve was prepared from the results listed in 
Table 31 and is shown in Figure 47 . 
Beer-Lambert law. 
It confo rms to 
ABSORBANCES OF SOLUTIONS OF THE Y-HYDROXY DERIVATIVE 
OF PHENYLBUTAZONE IN CHLORDFDRM:METHANOL (9:1) AT 
270 nm 
Absorbance Dilution (llg.ml- 1) 
0,11 5 
0,22 10 
0,41 20 
0,60 30 
0,78 40 
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Fig, 47 
Y-OH derivative of phenylbutazone I' g' ml -1 
Calibration Curve of the Y-hydroxy Derivative of 
Phenylbutazone in Chloroform:Methanol Solvent 
5. p-Y-DIHYDROXY DERIVATIVE OF PHENYLBUTAZONE 
5.1 Confirmation of Relative Chromatographic Purity 
Fresh ly prepared sol uti ons of the p-y-d i hydroxy deri va ti ve 
of phenylbutazone and oxyphenbutazone, which later was 
. used as a standard, were spotted on three Merck prepared 
plates, dried, the plates developed in the solvent systems 
listed in Table 32, examined under ultraviolet light, 
then sprayed and re-examined. Table 32 shows that, 
in each case, the solution of the p-Y-dihydroxy deri= 
Table 32 
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vative of phenylbutuzone produced only one visible spot 
under ultraviolet l l ght and after spraying; thus it was 
assumed that the sample was chromatographically pure. 
RELATIVE Rf VALUES OF THE p-Y-DIHYDROXY 
DERIVATIVE OF PHENYLBUTAZONE 
Solvents Relative Rf values 
III 0,30 
VII 0,15 
II 0,19 
6. 4-HYDROXY DERIVATIVE OF PHENYLBUTAZONE 
6.1 Synthesis 
The method of G Papa (39) for the synthesis of 4-hydroxy-
4-phenyl-1, 2-diphenyl -3, 5-pyrazolidinedione was modified 
and used by Professor Mathew to synthesise the 4-hydroxy 
derivative of phenylbutazone as follows: 
Phenylbutazone was dissolved in a solution of sodium 
methoxide in methanol and a solution of 35% w/w hydrogen 
peroxide in methanol added dropwise. Sodium hydroxide 
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-1 
solution (mNaOH = 6 mol · kg ) was gradually added to the 
cooled solution and the mixture stirred for 30 h. The 
solution was diluted with water, acidified with diluted 
sulphuric acid and the resultant precipitate taken up in 
ether and shaken with sodium bicarbonate solution. The 
alkaline extract was separated, reacidified and extracted 
with a large volume of ether. The ether was evaporated 
off and a white precipitate formed which was filtered and 
washed. The melting point of the crystals was 1310 C. 
6.2 · ·Cbhfirmation bf ·Chromatographic Purity 
Freshly prepared solutions of the 4-hydroxy derivative of 
phenylbutazone and oxyphenbutazone (used as a reference) 
were spotted on 5 pre-coated Merck 5 x 20 cm plates, which 
were dried and developed in the solvent systems listed in 
Table 33, examined under ultraviolet light, and sprayed. 
Table 33 shows that in each case the solution of the 4-
hydroxy derivative of phenylbutazone produced only one spot 
visible under ultravio l et light and after spraying and thus 
it was assumed that the sample was chromatographically pure . 
Tabl e 33 
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RELATIVE Rf VAl.UES OF THE 4-HYDROXY DERIVATIVE OF 
PHENYLBUTAZONE 
Solvents Relative Rf values 
XV 1,42 
III 1,07 
X 1,31 
II 1,20 
XXVI (a) 1,27 
CHAPTER X 
RADIO-CHEMICAL TECHNIQUES 
1. PREPARATION OF EFFICIENCY GRAPH FOR LIQUID SCINTILLATION 
SPECTROMETER 
The efficiency graph was prepared using a series of 6 standard samples 
of the same activity, one being unquenched and the others having 
increasing quenching. The unquenched sample had a dpm value of 
51 x 104 . The C channel of the spectrometer was set at the 14c 
setting and the A channel at L~U. Starting with the least quenched 
standard sample the counts of these samples in channels A and C were 
recorded. The upper and lower levels of A channel were adjusted 
until a combination was arrived at which gave a straight line graph 
(Figure 48) when the ratio of the counts in channel A against 
the counts in channel C were plotted against efficiency (counts in 
channel C x(Sl x 10 4). 
This graph was used to prov ide effi ci ency figures required to convert 
cpm to dpm in the liquid scintillation spectrometer experimental 
work which follows. 
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Efficiency Graph for Scintillation Spectrometer . 
2. METHODS OF MEASURING RADIOACTIVITY OF SAMPLES 
2.1 Liquids 
Samples (maximum volume 1 ml ) were pipetted into l.s.c. 
vials and mixed with 10 ml of scintillant. In some cases, 
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where it was necess~ry to use larger samples, 15 ml of 
scintillant was required to give a clear solution for 
counting. The background count was determined using . 
scintillant only. In all cases samples were· counted for 
10 mi n a:nd the counts in channels A and C were recorded. 
These were converted into dpm using the formula shown in 
Figure 49. 
Number of counts in 
. channel C· (sample) dpm = 
10 x E 
Number of counts in channel 
C (background) · 
10 x E 
where dpm = Disintegrations per minute 
E = Efficiency (from graph, Fi~""r'e 4 6) 
Fig. 49 Calculation of Disintegrations per Minute 
2.2 TLC Plates 
The area containing the radioactive material was marked 
under ultraviolet light and scraped off into a test tube. 
A kn·own volume of solvent was added and the contents mixed 
in a vortex shaker . The tube was centrifuged at 3 000 
r.p.m. for 15 min and an aliquot transferred to an l . s.c. 
vial. The solvent was evaporated under nitrogen, scintil= 
lant added and the radioactivity measured. 
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3. CONFIRMATION OF SPECIFIC ACTIVITY OF 14C PHENYLBUTAZONE 
A solution of unlabelled phenylbutazone was prepared by dissolving 
phenylbutazone (140 mg) in 10 ml methanol. A second solution of 
radioactive phenylbutazone was prepared by dissolving 14C phenylbuta= 
zone (15 mg) in 1,5 ml of dichloromethane. A portion of the radio= 
active solution (0,1 ml) was evaporated under nitrogen and 1 ml of the 
solution of unlabelled drug added to give a solution of phenylbuta= 
. -1 
zone containing 15 mg.ml 
A TLC plate was prepared from a slurry of Silica gel GF254 in 10% 
sodium thiosulphate solution, activated at 1000 C for 15 min and 4 
spots of about 0,5 ~l of the phenylbutazone solution applied to the 
plate. It was then dried, developed in solvent system XXVI and 
examined under ultraviolet light. The spots were marked, scraped 
off into 5 ml of chloroform:methanol (9:1) which was shaken and 
filtered. An aliquot of the filtrate (1 ml) was mixed with 2 ml 
chloroform:methanol (9:1), its absorbance was measured and the con= 
centration of phenylbutazone obtained from the calibration curve. A 
further aliquot of the filtrate (2 ml) was transferred to an l.s.c. 
vial, the solvent evaporated off under nitrogen, Bray's scintillant 
(10 ml) added and the radioactivity measured in the liquid scintilla= 
tion spectrometer. An equal area of the plate which showed no 
fluoresence under ultraviolet light was similarly treated to act as 
a blank. 
of the 14C 
From the results shown in Table 34 the average s . a. 
-1 phenylbutazone used was 10,84 KBq-mg . 
Table 34 SPECIFIC ACTIVITY OF 14C LABELLED PHENYLBUTAZONE 
~g/ml-1 Total weight of Weight of 14C 
Absorbance (1 in 3 Phenylbutazone Phenylbutazone Radioactivity 
sol uti on) in los oc o vial in l osoc o vial in dpm in vial iii ug in )1g 
0,26 20 120 8 516 
0,125 9,5 57 3,8 261 
0,15 11 ,2 67,2 4,48 292 
0,295 22,8 136,8 9,12 563 
Radioactivity 
in dpm in 1 mg 
6,45 0 104 
6,87 0 104 
6,52 0 104 
6,17 0 104 
6,50 0 104 
Specific 
Acti vity 
-, KBq omg • 
10,74 
11,47 
10,85 
10,28 
1 0,84 
.... 
w 
a 
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4. AUTORADIOGRAPHY 
4.1 Preparation of TLC Plate 
The radioactive material was spotted on a pre-coated Merck 
Silica gel F254 plate , developed in the appropriate solvent, 
examined under ultraviolet light and the spots lightly out= 
lined with a soft pencil. Dots of coloured radioactive 
ink were spotted on the edge of the plate . 
4.2 Preparation of Cassette to Hold Plate 
A cassette was made as shown in Figure 50 (45) which proved 
to be absolutely light proof and held the film against the 
plate in a non-skid fashion with even pressure. 
4.3 Photographic Procedure 
In the dark room Kodak Tri X PAN film was placed on the 
TLC plate in the cassette , the lid was sealed and the box 
stored in a drawer . After 28 days the film was removed 
and developed. 
The radioactive material showed up as shadows aga inst a 
clear background; the intensity of the shadows gave an 
indication of the amount of radioactive material present. 
Fi g. 50 
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Cassette for Autoradiography 
4.4. Photography Under Ultraviolet Light of TLC Plates Used for 
Autoradiography 
The plate was placed under an ultraviolet light and photo= 
graphed using an ultraviolet filter that obstructed the 
ultraviolet light but not the fluorescent light. It was 
planned to use the resultant photograph as a template for 
the identification of the radioactive spots on the auto= 
radi ograph • . 
However. this was found to be impracticable as the 
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photograph had to be taken from an angle which, a$ Figure 
51 illustrates, distorted the image. 
As an alternative a piece of tracing paper was placed on 
top of the TLC plate and a tracing made of the spots ob= 
served under ultraviolet light, as well as the marker ink 
spots. By superimposing this tracing on the photographic 
film and making certain t hat the marker ink spots were in 
apposition it was possible to ascertain which spots on the 
chromatogram showed radioactivity . 
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EXCRETION AND METABOLISM 
OF 
PHENYLBUTAZONE 
f. HAPTER XI 
EXCRETION STUDIES 
1. DOSING THE RAT 
Excretion studies were carried out on 4 rats, designated Rats 1, 2, 
3 and 4. Rat 1 was dosed with radioactive drug only, whereas Rats 
2, 3 and 4 were dosed with a mixture of radioactive and non-radioactive 
drug for the purpose of conserving the limited quantity of radioactive , 
'drug avail ab 1 e. The point of a Luer Lock needle (0 guage) was 
ground down to a smooth surface and protected with a small length of 
polythene tubing. The combined length of the needle and tubing was 
such ,that it could enter the stomach of the rat post-orally without 
causing injury. The needle was fitted to a 2 ml syringe, and the 
unit was used to dose the rats post-orally. 
1.1 ' Rat 1 
14 -1 C labelled phenylbutazone (12 mg - s . a. 10,84 KBq.mg ) 
was dissolved in 0,9 ml of sodium carbonate solution 
-1 (mNa CO = 1 mol ·kg ) and 0,3 ml of distilled water added 
2 3 -1 
to make a 10 mg.ml solution. A female Wistar rat, 
weighing 189 g was dosed post-orally with 1 ml of the 
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solution and placed in a glass Metabowl cage. A portion 
of the labelled phenylbutazone solution (0,1 ml) was diluted' 
to 10 ml with distilled water; to duplicate samples of this 
solution (0,5 ml) 10 ml Bray's scintillant was added and the 
radioactivity counted to determine the activity of the 
dosing solution (Solution A - Table 35). 
1.2 Rats 2, 3 and 4 
14C labelled phenylbutazone (7 mg - s.a. 10,84 KBq'mg- 1) 
and unlabelled phenylbutazone (43 mg) were dissolved in 3,6 
ml sodium carbonate solution (mNa co = 1 mol.kg-
1). The 
2 3 
solution was made up to 5 ml with distilled water to give 
1,4 mg labelled phenylbutazone per ml (Solution B). Rats 
2, 3 and 4, weighing 183, 190 .and 187 g respectively, were 
dosed post-orally with 1 ml of solution B and placed in 
individual glass Metabowl cages . Duplicate samples, each 
containing 0,05 ml of solution Band 10 ml of Bray's 
scintillant, were counted to determine the activity of 
the dosing solution (Table 35). 
2. COLLECTION OF SPECIMENS AND THEIR PREPARATION FOR LIQUID 
SCINTILLATION COUNTING 
Urine and faeces from each rat were collected at 24 h intervals, and, 
after collection, the Metabowls washed with a minimum volume of 
Table 35 DETERMINATION OF RADIOACTIVITY IN THE DOSE ADMINISTERED 
Counts per 10 min Radioactivity 
Sample taken Efficiency in Sample Taken for for Counting Channel Channel E Counting in A C dpm 
110 073 161 127 0,648 24 1+87 
Solution A 109 638 159 437 0,646 24 643 
101 058 244 552 0,764 31 974 
Solution B 113 645 282 889 0,779 36 279 
Background 94 352 0,827 38 
Total 
Radioactivity 
in dose in 
dpm 
4 947 000 
682 530 
I 
, 
I 
I ..... w 
" 
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distilled water. The volumes of the urines and washings 
were recorded. The samples of faeces were treated as 
follows in order to prepare a solution suitable for the 
measurement of radioactivity. Perchloric acid (15 ml of a 
60% solution) was added to the samples and the mixtures 
allowed to digest for 3 h before homogenising. The volumes 
of the homogenates were measured and aliquots, in l.s.c. 
vials, made alkaline with 40% sodium hydroxide and warmed. 
Five drops of 100 volume hydrogen peroxide were added and 
the mixture boiled for 5 min, care being taken to avoid 
spilling from effervescence. Finally they were neutralised 
to pH 7 with concentrated hydrochloric acid, scintillant 
added and the radioactivity measured. Scintillant was 
added to the samples of urine and Metabowl washings and the 
radioactivity measured . The background count of the 
scintillant used was also measured. 
recorded in Table 36. 
3. RADIOACTIVITY OF SAMPLES 
The results are 
3.1 Solutions of 14C Labelled Phenylbutazone Used for Dosing 
The samples of solutions of la belled phenylbutazone ad= 
ministered to the rats were counted for 10 min in the 
liquid scintillation spectrometer, and the total radio = 
activity in the dose calculated (Table 35) . 
Table 36 
Sample taken 
for counting 
Bray I s 
Scintillant 
Background 
Rat 1: 0,1 ml 
24 h urine 
Rat 1: 0,1 ml 
48 h uri ne 
Rat 1: 0,1 ml 
72 h urine 
Rat 1: . 
1,0 ml 24 h 
cage washing 
RADIOACTIVITY OF SAMPLES OF EXCRETION PRODUCTS OF RATS DOSED HITH 14C 
PHENYLBUTAZONE 
Volume Counts per 10 min Radioactivity Efficiency in dpm of 
of E sample taken S!Jecimen Channel Channel for cQunting A C 
94 352 0,827 38 
-
8,2 ml 123 083 250 212 0,743 34 051 
---------- ----------- -------------- ------------------
128 496 245 221 0,706 34 696 
3,0 ml 102 285 193 360 0,719 26 885 
---------- ------- ---- -------------- ------------ ------
100 853 188 137 0,716 26 238 
2,25 ml 31 476 53 496 0,674 7 899 
---------- ----------- -------------- ------------------
30 896 52 862 0,676 7 881 
29 982 39 778 0,614 6 441 24,54 ml 
r---------- ----------- -------------- ------------------
30 456 40 461 o 614 6 552 
Radioactivity 
in dpm of 
specimen 
2 818 627 
796 395 
173 580 
159 164 
..... 
W 
\D 
Table 36 (continued) 
Counts per 10 min 
Sample taken Volume 
for counti ng of Channel Channe 1 Specimen A C 
Rat 1: 60 698 . 87 946 1,0 ml 48 h 12,0 ml 1------------ ----------cage washing 71 081 98 070 
Rat 1: 13 838 18 827 1,0 ml 72h 12,5 ml 
----------- ----------cage washing 13 713 18 702 
Rat 1: 1,0 ml 27 803 37 937 24 h faeces 4,6 ml 
----------- ---- ------homogenate 28 150 38 215 
Rat 1: 1,0 ml 32 688 34 250 48 h faeces 84,0 ml 
------ ----- ----------homogenate 34 730 35 976 
Rat 1: 1,0 ml 28 498 30 335 72 h faeces 50,0 ml 
----------- ----------homogenate 27 973 29 579 
Radioactivity 
Efficiency in dpm of 
E sample taken 
for counting 
0,642 13 661 · 
--- -- ------ ---- ------------------
0,628 15 578 
0,623 2 984 
--------------- ------------------
0,624 2 959 
0,624 6 042 
--- -- -- --- - ----
------------------
0,620 6 164 
0,520 6 549 
-------------- -----------------
o 514 6 961 
0,532 5 664 
---------------r-----------------
0,523 5 619 
Radioactivity 
in dpm of 
specimen 
175 434 
37 144 
27 986 
567 420 
282 080 
t-' 
""" o 
Table 36 (continued) 
Volume Counts per 10 min Sample taken 
for counting of Channe 1 Channe 1 Specimen A C 
Bray's 
Sci nti 11 ant 73 281 
Background 
Rat 2: 0,1 ml 13,2 ml 10 434 21 562 24 h urine --- -------- ----------
10 018 20 788 
Rat 3: 0,1 ml 7,0 ml 17 841 35 902 24 h uri ne ----------- ----------
17 986 36 634 
Ra t 4: 0,1 ml 5,6 ml 19 750 39 153 24 h urine 
-----------r----------
20 391 39 473 
Rat 2: 4 856 78ll 1 ml 24 h 19,0 ml 
----------- ----------cage washing 4 848 7 621 
Rat 3: 7 041 11 247 1 ml 24 h 17,0 ml 
cage washing ---------- -----------7 264 II 359 
Radioactivity 
Efficiency in dpm of 
E sample taken 
for counting 
0,846 33 
-
0,740 2 881 
-------------- ------------------
0,742 2 769 
0,735 4 988 
-------------- ------------------
0,736 4 944 
0,730 5 330 
-------------- ------------------
0,728 5 389 
0,678 1 119 
-------------- ------------------
0,668 1 107 
0,674 1 636 
-------------- ---- -- ------------
0,668 1 667 
Radioactivity 
in dpm of 
specimen 
372 900 
347 620 
300 132 
21 147 
28 076 
..... 
-+> 
..... 
Table 36 (continued) 
Counts per 10 min 
Volume Sample taken 
of Channe 1 Channel for counting Specimen A C 
Rat 4: 6 584 10 965 1 ml 24 h 20,0 ml 
cage washing ---------- -----------6 466 11 096 
Rat 2: 0,1 ml 3 209 6 354 
48 h urine 9,8 ml ---------- -----------2 795 5 734 
Rat 3: 0,1 ml 4411 8 181 
48 h urine 7,0 ml ---------- -----------4 386 8 569 
Rat 4: 0,1 ml 4 405 6 182 
48 h uri ne 4,5 ml ---------- -----------4 438 6 140 
Rat 2: 1 355 2 350 
r ml 48 h 17,0 ml ---------- -----------
cage washing 1 456 2 470 
Rat 3: 2 578 4 024 
1 ml 48 h 19,0 ml ---------- --------- --
cage washing 2 632 4 377 
Rat 4: 4 405 6 182 
1 ml 48 h 20,0 ml 
----------- ------------
cage washing 4 438 6 140 
Efficiency 
E 
0,686 
---------------0,694 
0,731 
--------------
0,737 
0,718 
--------------
0,728 
0,632 
---------------
0,632 
0,714 
---------------
0,692 
0,668 
-- ----- -------
0,686 
0,632 
---------------0,632 
Radioactivity 
in dpm of 
sample taken 
for counti ng 
1 565 
------------------
1 566 
836 
------------------
745 
1 106 
------------------
1 144 
945 
------------------
939 
296 
------------------
324 
570 
------------------
605 
945 
------------------
939 
Radioactivity 
in dpm of 
specimen 
31 310 
77 469 
78 750 
60 255 
5 270 
11 163 
18 840 
..... 
-I'> 
N 
-Table 36 (continued) 
Volume Counts per 10 min Sample taken 
for counting of Channel Channe 1 specimen A C 
Bray's 
Scintill ant 111 331 
Background 
Rat 2: 0,1 ml 953 1 911 
72 h urine 15,0 ml ----------- -----------957 1 861 
Rat 3: 0,1 ml 1 302 2 499 
72 h urine 6,5 ml ----------- -----------1 261 2 437 
1 504 2 869 Ra t 4: 0,1 ml 
72 h urine 5,8 ml ----------- -----------1 200 2 554 
Rat 2: 549 1 021 
1 ml 72 h 23,0 ml ----------- -----------
cage washing 605 1 131 
Rat 3: 1 081 1 707 
1 ml 72 h 19,0 ml ----------- -----------
cage washing 1 111 1 706 
Rat 4: 736 1 280 
1 ml 72 h 19,0 ml ----------- -----------
cage washing 1 024 1 623 
--
-- -- -
Radioactivity 
Efficiency in dpm of 
E sample taken 
for counting 
0,820 40 
-
0,733 221 
-------------- ------------------
0,730 215 
0,722 306 
-------------- ------------------
0,726 296 
0,706 366 
--------------- ------------------
0,744 303 
0,720 102 
-------------- ------------------
0,714 116 
0,670 215 
------- ----- -- -- ------ --- ---- - ----
0,664 217 
0,698 143 
-------- ------ ------------------
0,670 202 
- - - ---- -- --- ---
Rad i oacti vity 
in dpm of 
specimen 
32 700 
19 565 
19 401 
2 507 
4 104 
3 268 
, 
I-' 
..,. 
w 
Table 36 (continued) 
Volume Counts per 10 min Sample taken 
for counting of Channe 1 Channel specimen A C 
Bray I s 132 302 
Scintillant ---------- -----------
Background 115 300 
Rat 2: 0,1 ml 241 469 
96 h urine 18,5 ml ---------- -----------230 524 
Rat 3: 0,1 ml 330 614 
96 h ur i ne 6,5 ml ---------- -----------325 618 
Rat 4: 0,1 ml 290 . 557 
96 h urine 5,5 ml ---------- -------- ---357 762 
Rat 2: 271 533 
1 ml 96 h 32,0 ml ---------- -----------
cage washing, 267. 521 
Rat 3: 626 1 002 
1 ml 96 h 22,0 ml ---------- -----------
cage washing 634 1 037 
Rat 4: 829 1 207 
1 ml 96 h 23,0 ml --- ----- -- -----------
cage washing 839 1 266 
Radioactivity 
Efficiency in dpm of 
E sample taken 
for counting 
0,764 
-------------- 39 
0,788 -
0,726 26 
-------------- ------------------
0,762 30 
0,715 47 
-------------- ------------------
0,720 47 
0,724 38 
-------------- ------------------
0,749 63 
0,730 34 
------------- - ------------------
0,727 33 
0,673 110 
-------------- ---- ------ --- --- --
0,679 114 
0,645 148 
-------------- ------------------
0,657 154 
Radioactivity 
in dpm of 
specimen 
5 180 
i 
I 
3 055 , 
2 778 
1 073 
2 464 
3 473 
I-' 
.po 
.po 
Table 36 (continued) 
Vo 1 ume Counts per 10 min Sample taken 
for counting of Channel Channe 1 specimen A C 
Rat 2: 0,5 ml 2 281 2 487 
24 h faeces 40,0 ml ~------ ----- ----------
homogenate 2 340 2 307 
Rat 3: 0,5 ml 3 737 3 839 
24 h faeces 29,0 ml ~-------- --- ----------homogenate 3 935 3 706 
Rat 4: 0,5 ml 1 023 1 265 
24 h faeces 30 ,0 ml -- -------- - ----------
homogenate 740 850 
Rat 2: 0,5 ml 3 360 3 606 
48 h faeces 35,0 ml ~----------- ----------
homogenate 3 411 3 294 
Bray IS 140 355 
Scinti 11 ant ~----------- ----------
Background 143 348 
Rat 3: 0,5 ml 2 998 3 589 
48 h faeces 28,0 ml ~--- -- ------ ----------
homogenate 3 157 3 808 
Rat 4: 0,5 ml 4 864 4 952 
48 h faeces 36,0 ml ~----------- ----------
homogenate 3 614 4 256 
Radioactivity 
Effi ci ency in dpm of 
E sampl e taken 
for counti ng 
0,542 420 
-------------- ------------------
0,495 427 
0,512 711 
-------------- ------------------
0,465 758 
0,589 176 
-------------- ------------------
0,560 113 
0,531 640 
--- ----------- ------------------
0,482 644 
0,798 
-------------- 45 
0,776 -
0,576 578 
-------------- ------------------
0,578 613 
0,498 949 
-------------- ------------------
0,572 699 
- - - - - --
Radioactivity; 
in dpm of 
specimen 
33 880 
42 601 
8 760 
44 940 
33 348 
: 
I 59 328 
j 
,.... 
..,. 
<Jl 
Table 36 (continued) 
Volume Counts per 10 min Sample taken 
for counting of Channel Channel specimen A C 
Rat 2 0,5 ml 1 457 1 453 
72 h faeces 38,0 ml -- ----- --- -----------
homogenate 1 195 1 387 
Rat 3 0,5 ml 1 522 1 615 
72 h faeces 36,0 ml 
---------- -----------
homogenate 1 .579 1 523 
Rat 4 0,5 ml 1 977 2 169 72 h faeces 32 ,0 ml 
homogenate ---------- -----------2 041 2 134 
Rat 2 0,5 ml 806 1 043 
96 h faeces 29,0 ml ---------- -----------
homogenate 896 1 097 
Rat 3 0,5 ml 426 613 
96 h faeces 26,0 ml ---------- -----------
homogenate 390 646 
Rat 4 0,5 ml 510 715 
96 h faeces 27,0 ml ---------- -----------
homogenate 619 968 
Radi oacti vity 
Efficiency . in dpm of 
E sample taken 
for counting 
0,492 250 
--------------- ----------------
0,560 202 
0,523 264 
--------------- ----------------
0,480 272 
0,539 357 
--------------- ----------------
0,518 367 
0,605 127 
--------------- -------- -- ---- --
0,631 129 
0,642 51 
--------------- ----------------
0,682 49 
0,636 67 
--------------- ----------------
0,668 100 
Radioactivity 
in dpm of 
specimen 
17 176 
19 296 
23 168 
7 424 
2 600 
4 509 
! 
..... 
.,. 
en 
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3.2 Specimens of Urine and Faeces 
The samples of urine and faeces prepared for liquid 
·scintillation counting were counted for 10· min and the 
counts converted to radioactivity in dpm. Table 36 
shows the radioactivity in each sample and the total radio= 
activity. 
4. RATE OF EXCRETION IN URINE AND FAECES 
The rate of excretion of phenylbutazone and its metabolites in the 
·urine and faeces used in this study was calculated as a combined total 
from the measurement of the radioactivity of the samples recorded in 
Table 36. The radioactivity of the Metabowl cage washings was com= 
bined with that of the appropriate urine sample, as it was considered 
that this radioactivity emanated from urine which had dried on the 
surface of the glass Metabowl between collection times. The rate of 
excretion fn urine and faeces over a period of 96 h is shown in 
Table 37. 
Table 37 RATE OF EXCRETION OF DOSE 
Specimen RAT 1 RAT 
dpm % of dose dpm 
24 h urine 2 818 627 60,2 372 900 
48 h urine 796 395 19,8 77 469 
72 h uri ne 173 580 4,3 32 700 
96 h urine - - 5 180 
TOTAL URINE 84,3 
24 h faeces 27 986 0,6 33 880 
48 h faeces 567 420 11 ,5" 44 940 
72 h faeces 28 208 0,6 17 176 
96 h faeces - - 7 424 
TOTAL FAECES 12,6 
TOTAL 
RECOVERY 96,8 
- -
--- --- L---__ - - -_._-
2 RAT 3 
% of dose dpm % of dose 
57,7 347 620 55,0 
12,2 78 750 13,1 
5,2 19 565 3,3 
1,0 3 055 0,8 
76,1 72,2 
5,0 42 601 6,2 
6,6 33 348 4,9 
2,5 19 296 2,8 
1,1 2 600 0,4 
15,2 14,3 
91,2 86,5 
RAT 
dpm 
300 132 
60 255 
19 401 
2 778 
8 760 
59 328 
23 168 
4 509 
4 
% of dose 
48,6 
11,6 
3,3 
0,4 
6" A 
--2.l2. 
1,3 
8,7 
3,4 
0,7 
14,1 
78,5 
...... 
-I'> 
00 
CHAPTER XII 
IDENTIFICATION OF PHENYLBUTAZONE AND ITS 
METABOLITES IN URINE AND FAECES 
1. COLLECTION OF SPECIMENS 
A female Wistar rat, weighing 201 g, was dosed post-orally with 1 ml 
of a solution containing 10 mg.ml- 1 of 14C labelled phenylbutazone 
(s.a . 10,84 KBq.mg-1). The rat was placed in a Metabowl, which had 
its collection flasks suspended in methanol at -200 C. The apparatus 
was examined regularly and frozen urine in the glass tube connected 
to the collection flask was carefully melted using a hot air blower. 
The urine (17,6 ml) and faeces (6,43 g) were collected after 48 h. 
2. EXTRACTION OF NON-WATER SOLUBLE METABOLITES AND DECOMPO= 
SITION PRODUCTS FROM URINE 
After acidification of the urine with 20% sulphuric acid 8 ml of 
dichloromethane was added and the mixture shaken and centrifuged. 
The solvent layer was removed and extraction continued until the 
radioactivity in the urine layer remained steady . The solvent 
150 
fractions were combined, evaporated to dryness under nitrogen and 
dissolved in I,D ml of dichloromethane. The aqueous l ayer was re= 
tained for examination of water soluble metabolites. 
3. EXAMINATION OF THE NON-AQUEOUS EXTRACT FOR METABOLITES 
·AND DECOMPOSITION PRODUCTS 
3.1 TLC Analysis 
Two Merck 5 x 20 cm plates were prepared by applying to each plate 
small spots (10 ~l) of the dichloromethane extract of urine and 
1% oxyphenbutazone in dichloromethane on a base line approximately 
1 cm apart. One plate was developed in solvent system XV and 
the other in solvent system III. They were then dried and 
sprayed. The relative Rf values and the colour reactions of the 
eluted spots were compared with those obtained for phenylbutazone 
and its possible metabolites (Table 38). 
These results indicated that the following substances were present 
in the urine of rats treated with phenylbutazone: 
Phenylbutazone 
Oxyphenbutazone 
Y-OH Derivative of phenylbutazone as the ring lactone 
isomer and the straight chain hydroxyl isomer 
p-Y-Dihydroxy derivative of phenylbutazone 
Table 38 
Solvent 
XV 
III 
THE RELATIVE Rf VALUES AND COLOUR REACTION OF ELUTED SPOTS OF URINE EXTRACT 
COMPARED WITH THOSE OF PHENYLBUTAZONE AND POSSIBLE METABOLITES 
Relative Rf value and colour reactions Relative Rf values and colour reactions ob= 
obtained from chromatograms of standard tained from chromatograms of urine extract 
compounds from rat dosed with 14C phenylbutazone 
Relative Colour Spot Relative Colour Rf value Reaction Rf value Reaction 
Phenyl butazone 2,00 Green grey 1 2,10 Green grey 
Y-OH (Ring lactone 
form) derivative of 1,81 Violet 2 1,85 Violet 
of phenylbutazone 
4-0H Derivative 1,41 Green grey 3 1,45 Green grey of phenylbutazone 
Oxyphenbutazone 1,00 Yell ow 4 1,00 Yellow 
Oxyphenbutazone 1,00 Yell ow 1 1,00 Yell ow 
4-0H Der ivat ive of 0,80 Yellow 2 0,79 Yellow oxyphenbutazone 
Y-OH (Straiqht 
cha in hydroxyl 0,55 Brown 3 0,53 Brown form) derivative Orange Orange 
of phenylbutazone 
p-Y-DiOH derivative 0,31 Yell ow 4 0,30 Yellow of phenylbutazone 
...... 
'" ...... 
152 
4-0H Deri vat ive of pheny'l butazone 
4-0H Derivative of oxyphenbutazone 
In order to confirm these findings autoradiographic studies were 
undertaken. 
3.2 Autoradiographic Analysis 
Four light pencil marks, 1 cm apart were made on the base line 
of a Merck 5 x 20 cm TLC plate (Plate a) and a dichloromethane 
extract of urine (10 ~l) was applied as a small spot on each of 
these marks. After drying 5 ~l of a 1% solution in dichlorome= 
thane of one of the followiD9 was superimposed on each of these 
spots to act as a reference standard: 
1 
2 
phenylbutazone 
Y-hydroxy (ring lactone form) derivative of phenylbuta= 
zone 
3 4-hydroxy derivative of phenylbutazone 
4 oxyphenbutazone 
After drying the plate (Plate a) was developed in Solvent System XV. 
A second Merck 5 x 20 cm TLC plate (Plate b) was similarly 
spotted with a dichloromethane extract of urine, and reference 
standards superimposed as follows: 
5 oxyphenbutazone 
7 Y-hydroxy (straight chain hydroxyl form) derivative of 
phenylbutazone 
153 
8 p-Y-dihydroxy derivative of phenylbutazone 
After drying, this plate /Plate b) was developed in solvent 
system II 1. 
The plates were examined under ultraviolet light and the fluores= 
cent spots lightly outlined with a soft pencil. Dots of radio= 
active ink were spotted at the corners of each plate to act as 
.markers. The plates were then placed in the casette and, in 
the dark room, covered with Kodak Tri-X Pan film and allowed to 
stand for 28 days. The film was then removed and developed. 
A tracing of the outlined pencil spots (Figures 52 & 53) together 
with the ink spots on each plate was made with thin tracing 
paper. The tracing paper was then placed on top of the photo= 
graphic film to act as a template, making sure that the ink spots 
were superimposed. Figures 52 & 53 show a photographic reproduction 
of these autoradiographs and Table 39 lists the metabolites identified 
in the dichlorometliane extrac.t of the urine, together with an 
indication of their concentrations as judged by the size and 
density of the spot on the photographic film. 
These results (Table 39) confirmed the identification of phenyl= 
butazone and its metabolites and decomposition products as 
indicated by thin layer chromatography . 
As these results did not agree with those reported by Bakke 
it was considered important to repeat his chromatographic 
Plate a 
Fig . ,52 
154 
~ 
1 
Solvent System XV 
1. Phenylbutazone 
2. Y-hydroxy derivative 
(ring lactone form) 
of Phenylbutazone 
3. 4-hydroxy derivative 
of Phenylbutazone 
4. Oxyphenbutazone 
AutoradiographofOrganic Solvent Extract of Urine 
, froin' a Rat Treat~d 'with ',T4c - ' PhenyibutaZ()n~ ' ~i1:h 
, - Superiinposed Tracinssof Marker Spots of Official 
Standards 
---
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Pl ate b So 1 vent System I II 
Fi g. 53 
5. Oxyphenbutazone 
6. 4-hydroxy derivative 
of Oxyphenbutazone 
7. Y-hydroxy derivative 
(straight chain hydroxyl 
form) of Phenylbutazone 
8. Para-Y-dihydroxy 
derivative of 
Phenylbutazone 
' Autoradi ograph ' of Organ; c Sol vent Extract of Urine 
" ftCiriJ 'a 'Rat 'Tteated"'with 14C Phenylbutazone, \·rith 
SUEerimposed Tracings of Marker Spots of Official 
Standards 
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Table 39 PHENYLBUTAZONE AND ITS POSSIBLE METABOLITES ·IDENTIFIED 
ON THE AUTORADIOGRAPH REPRODUCED IN FIGURES 52 & 53 
Y-OH (Straight chain hydroxyl form) derivative of 
phenylbutazone 
y-OH (Ring lactone form) derivative of phenylbutazone 
Oxyphenbutazone 
4-0H Derivative of oxyphenbutazone 
p-Y-diOH Derivative of phenylbutazone 
Phenylbutazone 
4-0H Derivative of phenylbutazone 
+++++ 
++++ 
+++ 
+++ 
++ 
+ 
+ 
The number of + indicate the approximate concentration 
shown by the size of the spots and the intensity of the 
radioactivity. 
study using his solvent systems. The results of this experiment 
are shown in Table 40. 
4. EXAMINATION OF URINE FRACTION AFTER EXTRACTION WITH 
DICHLOROMETHANE 
The urine fraction remaining after extraction with dichloromethane was 
evaporated on a Rotavator at 60°C to 1,07 ml and 10 ~l spotted on each 
of 2 pre-coated Merck 5 x 20 cm plates (Plates 1 and 2) (Spot i). 
The balance of the extract was incubated at 37°C for 3 h with 0,1 
ml S-gluc4ronidase/arylsulfatase and 1,0 ml acetate buffer (pH 4,5) . 
After hydrolysis the mixture was acidified to pH 1 with sulphuric 
Table 40 
Standard 
Phenylbutazone 
Y-OH (Ring lactone 
form) derivative 
of phenylbutazone 
4-0H Derivative of 
phenylbutazone 
Oxyphenbutazone 
4-0H Derivative of 
oxyphenbutazone 
RELATIVE Rf VALUES OF STANDARD SAMPLES OF PHENYLBUTAZONE AND ITS 
METABOLITES 
Solvent Systems Used in This Study Solvent Systems Used by Bakke 
Cyclohexane: 
Dichloromethane: chloroform: 
III XV acetone methano 1 : 
(9:1) acetic acid (60:30:5:5) 
2,15 2,10 2,55 
1,79 1,40 1,05 
1,43 1,27 1,21 
1,0 1,0 1,0 1,0 
0,77 0,34 0,56 
Y-OH (Straight chain 
hydroxyl form) 0,56 0,24 0,19 derivative of 
phenyl butazone 
p-Y-Dihydroxy 
derivative of 0,29 0,00 0,19 
phenylbutazone 
...... 
(J1 
..... 
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acid, and 1,5 ml transferred to a nipple tube with 1,2 ml of dichloro= 
methane, mixed on the vortex shaker, centrifuged and 10 ~l of the 
supernatant dichloromethane layer spotted on plates 1 and 2 (Spot ii). 
The same volume of the aqueous layer was also spotted on plates 1 and 
2 (Spot iii). Plate 1 was used for TLC analysis and plate 2 for 
autoradiography. 
4.1 Examination for Me tabolites Hydrolysed by 
e~Glucuronidase/aryls ulfatase 
4.1.1 Chromatographic Examination 
A third pre-coated Merck 5 x 20 cm plate (control plate) was 
spotted with standard oxyphenbutazone solution which con= 
tained the 4-hydroxy derivative as a decomposition product. 
Plate 1 and the control plate were developed in solvent sys= 
tern III, sprayed and tracings of the spots on the plates were 
prepared. The Rf values are listed in Table 41. The 
chromatogram of plate 1 was identical to that of plate 2 
shown in the tracing in Figure 54. 
Compounds 1 and 2 had similar Rf values to oxyphenbutazone 
and its 4-hydroxy derivative respectively and exhibited the 
same colour reactions. Compound 3 could not be identified 
and did not have the characteristics of any of the recorded 
metabolites or decomposition products of phenylbutazone 
(vide infra). 
Table 41 
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~f VALUES AND COLOUR REACTIONS OF OXYPHENBUTAZONE, 
ITS 4-HYDROXY DERIVATIVE AND THE COMPOUNDS PRESENT 
IN THE DICHLOROMETHANE EXTRACT OF THE HYDROLYSATE 
Compound Rf Value Colour Reaction 
Oxyphenbutazone 0,53 Yell ow 
4-Hydroxy derivative of oxyphenbutazone 0,40 Yellow 
Compound 
Compound 
Compound 
1 0,52 Yellow 
2 0,39 Yellow 
3 0,24 Orange 
4.1. 2 Autoradiographic Examination 
Plate 2, spotted with the aqueous layer after the extraction 
of the urine with dichloromethane, the dichloromethane 
extract of the hydrolysate of this aqueous layer and the 
aqueous layer remaining after the extraction of this hydro= 
lysate, was . developed with solvent system III, and the plate 
dried. A tracing of the chromatogram visualised under 
ultraviolet light and a photographic negative of the auto= 
radiograph were prepared as previously described. The 
tracing superimposed on the print of the autoradiograph is 
shown in Figure 54. The Rf value of the spots were the 
same as those given in Table 41 . 
Plate 2 
( 
{ /., 
Fig . 54 
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i. Aqueous extract of urine 
from rat dosed with 
14C Phenylbutazone 
ii. Dichloromethane extract 
of the hydrol ysate of 
the aqueous extract i 
iii. Aqueous layer from ii 
Autoradiograph of Aqueous Layer of Urine After Solvent 
~xtraction Before and After Enzyme Hydrolysis With 
Superimposed Tracings of Fluorescence Visible Under 
Ultraviolet Light 
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These results confirmed that conjugates of oxyphenbutazone 
were metabolites of phenylbutazone. The presence of the 
4-hydroxy derivative of oxyphenbutazone in the dichlorome= 
thane extract of the hydrolysate indicated that the conjugate 
of this derivative could also be a metabolite Dr it could 
be a decomposition product. However, radioactivity was not 
detected in the position of Compound 3 (Table 41) indica= 
ting that it was not a metabolite Dr decomposition product 
of phenylbutazone. On the autoradiograph there was evidence 
of radioactivity at a spot whose Rf value was similar to the 
second decomposition product of oxyphenbutazone. There was 
also evidence of considerable radioactivity at the origin of 
the plate where the aqueous residue had been spotted. 
4.2 Examination for Metabolites not Hydrolysed by 
S-Glucuronidase/arylsulfatase 
A 20 x' 20 cm TLC plate was prepared from a slurry of Silica gel 
PF254 in 10% sodium thiosulphate solution, activated at 100
0 C for 
15 min and spotted with 15 ~l of the aqueous layer remaining 
after extraction of the hydrolysate with dichloromethane. The 
plate was subjected to two dimensional development according to 
the method of Dieterle (22) using solvent system XXVII, examined 
under ultraviolet light, the fluorescent spots marked and a 
tracing prepared (Figure 5~). 
8 c 
D 
'[}E F. 
/!) 
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G f-o 
A. Phenylbutazone 
B. Oxyphenbutazone 
C. Y-Hydroxy derivative of 
phenylbutazone 
D. Para-Y-dihydroxy derivative 
of phenylbutazone 
E. C-4 glucuronide of phenyl = 
butazone 
F. Unknown 
G. C-4 glucuronide of the ·Y-
i hydroxy derivative of phenylbutazone START ""-________________________ ~;:::~1st Dimension 
~ 2nd Dimension 
Fi g. 55 COpy of .an Autoradi ograph of 2 Dimensi'ona 1 TLCofRadio= 
~cti~e Sub~tances iri ·Hum'n U~ine 
0 I 0 0 
1st Dimens ion 
~ 2nd Dimension 
Fig. 56 Chromatogram of Non-hydrolysable Water Soluble Metabo~ites 
of Phenylbutazone in Urine of Rats Treated with Phenyl= 
butazone 
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A comparison of the relative positions of the spots present on 
this chromatogram with the position of the spots present in the 
chromatogram reported by Dieterle (22) (Figures 55 and 56) which 
were prepared by the same procedure suggests that these metabo= 
lites could be, either the C-4 glucuronide of the Y-hydroxy 
derivative of phenylbutazone or some unidentified polar metabolite. 
As Dieterle did not report the Rf values obtained from his 
chromatogram, and as standard compounds were not available, no 
definite conclusions could be drawn from this chromatographic 
procedure. 
5. EXAMINATION OF METABOLITES PRESENT IN THE FAECES OF RATS DOSED 
WITH 14C LABELLED PHENYLBUTAZONE 
5.1 Extraction and Enzymatic HydrolysiS of Faeces 
A portion of faeces collected from a rat dosed with 10 mg 14C 
labelled phenylbutazone was homogenised in water, the specimen 
filtered, the filtrate ~4,7 ml) freeze dried and reconstituted 
in 3 ml acetate buffer (pH 4,5) . A portion of this solution 
(2 ml) was incubated at 370 C for 3 h with 0,2 ml acetate buffer 
o-..t.. f.> - 'J I ..... c~ ... o"'; ""0-, <-/S"-I p~"'- ~e. . 
(pH 4,5)A Following incubation the hydrolysate was shaken with 
1,2 ml of dichloromethane and centrifuged. An aliquot of the 
dichloromethane layer (0,9 ml) was evaporated to dryness, the 
residue dissolved in 0,2 ml of dichloromethane and 2 samples 
of 50 ~l each were added to 10 ml quantities of Aquagel for 
Table 42 
Dichloromethane 
f ractio n 
Aqueous 
fraction 
RADIOACTIVITY IN AQ~EOUS AND DICHLOROMETHANE FRACTIONS OF THE HYDROLYSATE 
OF THE EXTRACT OF FAECES FROM A· RAT DOSED WITH 14C PHENYLBUTAZONE 
Radioactivity Vol ume Volume Radi oacti vity Total Total 
(in dpm) in in of (in dpm) in Radioactivity 
vi a 1 vi a 1 Sample Sample Volume (; n dpm ) 
4 250 200 18 000 
50 III III ex 1,2 ml 20 928 
3 618 0,9 ml 14 472 
13 550 108 400 
0,5 ml 4 ml 4,0 ml 112 .576 
14 595 116 760 
..... 
'" ..,. 
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measurement of radioactivity. Also 2 samples each of 0,5 ml of 
the aqueous fraction of the hydrolysate remaining after extraction 
with dichloromethane were added to 10 ml quantities of Aquagel 
for measurement of radioactivity. From the measurement of the 
radioactivity of these samples the proportion of the radioacti= 
vity emanating from the hydrolysable and non-hydrolysable metabo= 
lites present in the faeces was calculated (Table 42). 
From the radioactive measurements given in Table 42, it can be 
seen that the major proportion of the metabolites in the faeces 
consists of compounds which are not hydrolysed under these 
conditions by e-gl ucuronidase/aryl sul fatase enzyme and therefore 
are not likely to be O-glucuronides or O-sulphates. 
5.2 Chromatographic Examination of the Organic and Aqueous 
Fractions of Extracts of Faeces Following Enzymic Hydrolysis 
Two 5 x 20 cm TLC plates (1 and 2) were spotted with the recon= 
stituted filtrate of the faeces homogenate (spot i), the 
dichloromethane extract of the hydrolysate (spot ii), the aqueous 
fraction remaining after this extraction (spot iii) and a soluT 
tion .of standard oxyphenbutazone containing an impurity of its 
4-hydroxy derivative (spot iv) . They were developed in solvent 
system III and dried. A tracing of the fluorescence visible on 
plate 1 was prepared (Figure 57) before the plate was sprayed. 
This plate was used to estimate the distribution .of the radio= 
@ 
0 
rI'1 
... 
i 
Fig. 57 
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Plate 1 
0 
0 
ii 
i - reconstituted filtrate of 
faeces homogenate 
ii - dichloromethane extract 
of hydrolysate of (i) 
iii - aqueous residue from 
(i i ) 
iv - solution of standard 
oxyphenbutazone 
Q 8 - non-fl uorescent control 
for l.s.c. 
9 - oxyphenbutazone 
0 10 - 4-0H derivative of oxyphenbutazone 
Colour reactions 
it-YellOW 
10 
0 
r;;') 
-iii iv 
Chromatogram of Fracti onsof Homogenate 'of Fa'eces from 
'a Rat Dosed with 14C Phenylbutazbne 
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activity in the spots. Plate 2 was subjected to autoradio= 
graphy. 
As can be seen from Figure 57 the dichloromethane extract of the 
hydrolysate contained substances with Rf values and colour 
reactions similar to oxyphenbutazone and its 4-hydroxy derivative. 
In order to ascertain whether the spots on the plate actually 
represented metabolites in the faeces, spots 1, 2, 3, 6 and 7 
were scraped off into 5 ml water and spots 4, 5 and 8 into 5 ml 
chloroform: methanol (9:1). Spot 8 was used as a control. The 
test tubes were shaken, centrifuged and 3,5 ml of the filtrate 
evaporated to dryness in an l.s.c. vial. Aquagel (10 ml) was 
added to each vial and the radioactivity measured. The results 
are recorded in Table 43. 
Table 43 
Spot 
1 
2 
3 
4 
5 
6 
7 
8 
DPM OF ELUATES FROM SPOTS SHOWN IN THE CHROMATOGRAM 
REPRODUCED IN FIGURE 57 
Radioactivity 
634 
392 
387 
779 
1 062 
509 
290 
386 
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These results showed that spot 5, corresponding to oxyphenbutazone 
and spot 4, corresponding to the 4-hydroxy derivative of oxyphen= · 
butazone, both contained radioactivity and were, therefore, meta= 
bolites of the 14C phenylbutazone given to the rat. Radioactivity 
was also apparent at the origin of the spot of the aqueous sample. 
5.3 Autoradio0raphic Examination of the Organic and Aqueous 
Fractions of Faeces Following Enzymic Hydrolysis 
Plate 2 (vide 5.2) was examined under ultraviolet Tight and a 
tracing prepared of the fluorescent spots, before it was placed 
in the cassette with the Kodak Tri-X Pan film for 28 days. At 
the end of this period it was developed. The autoradiograph 
was compared with the superimposed tracing, as illustrated in 
Figure 58, and showed a clearly defined spot with an Rf value 
similar to oxyphenbutazone and a weaker spot with an Rf value 
similar to the 4-hydroxy derivative of oxyphenbutazone. There 
was aho considerable radioactivity at the origin of the 
aqueous fractions . 
Fig. 58 
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Plate 2 
o 
\" ,:,r-- -
i. Reconstituted filtrate 
of faeces homogenate 
ii. Dichloromethane extract 
of hydrolysate of i 
iii. Aqueous residue from ii 
iv. Solution of standard 
Oxyphenbutazone 
9. Oxyphenbutazone 
10. 4-hydroxy derivative 
of Oxyphenbutazone 
Autoradiogr~ph of Fractions of Homosenate of Faeces 
Before and After Enzymatic Hydrolysis. Hith 
Superimposed Tracings of Fluorescence Visible Under 
Ultraviolet Light 
170 
6. CONCLUSION 
The results of these experiments indicated that after dosing rats with 
phenylbutazone the following compounds were present in their urine: 
Phenylbutazone 
Oxyphenbutazone 
Y-Hydroxy (straight chain hydroxyl form) derivative of phenyl= 
butazone 
y-Hydroxy (ring lactone form) derivative of phenylbutazone 
Para-Y-dihydroxy derivative of phenylbutazone 
4-Hydroxy derivative of oxyphenbutazone 
Conjugates of oxyphenbutazone (either O-glucuronide or a-sulphate 
or a mixture of a-glucuronide · and O-sulphate) 
Conjugates of the 4-hydroxy derivative of oxyphenbutazone (either 
a-glucuronide or O-sulphate or a mixture of O-glucuronide and 
O-sulphate) were possibly present 
C-4 glucuronide of the y-hydroxy derivative of phenylbutazone 
was possibly present but its identity could not be confirmed 
Other non-hydrolysable, water soluble compounds were isolated 
but could not be identified. 
In the faeces the following compounds were found: 
Conjugates of oxyphenbutazone (either O-glucuronide or O-sulphate 
or a mixture of O-glucuronide and O-sulphate) 
Conjugates of the 4-hydroxy derivative of oxyphenbutazone (either 
a-glucuronide or O-sulphate or a mixture of O-glucuronide and 
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O-sulphate) were possibly present . 
Non-hydrolysable, water soluble compounds were isolated, but 
not identified. 
CHAPTER XIII 
QUANTITATIVE STUDIES 
1. COLLECTION AND TREATMENT OF URINE FOR QUANTITATION OF 
METABOLITES 
Quantitative studies were carried out on water insoluble metabolites 
in the 0 - 48 h urine of . rats dosed with 14C phenylbutazone, as it 
was found from the excretion studies that urinary excretion was almost 
complete within this period. A female Wi star rat was dosed post-
orally with 10 mg 14C labelled phenylbutazone (s.a. 10,B4 KBq.mg- 1). 
The urine was transferred to a vacuum flask containing 2 ml of sodium 
thiosulphate solution 
solution containing 
tazone and 4 mg.ml-1 
( -1 mNa S 0 = 1 mol ·kg ) and 5 ml of a methanolic 
2 2 31 -1 8 mg.ml phenylbutazone, 6 mg.ml oxyphenbu= 
of the Y-hydroxy derivative of phenylbutazone was 
added. The methanol was removed by bubbling nitrogen through the 
mixture overnight, care being taken to ensure that the tube from the 
nitrogen remained deep in the solution throughout this period. After 
acidification with 20% sulphuric acid, the urine mixture was shaken 
with 14 ml of dichloromethane and then centrifuged . The solvent 
layer was removed and extraction continued until the radioactivity of 
the urine layer remained constant. The solvent fractions were 
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combined, evaporated to dryness under nitrogen and re-dissolved in 
1,1 ml dichloromethane. 
2. TLC OF DICHLOROMETHANE EXTRACT 
One ml of the dichloromethane extract was applied, by means of a 
chromatocharger, to an activated preparative plate containing 10% 
sodium thiosulphate. The plate was dried, developed in solvent 
system XXVI, and examined under ultraviolet light. Eight bands were 
visible, as shown in Figure 59, and their positions marked. 
3. ISOLATION OF COMPOUNDS IN BANDS ON THE PREPARATIVE PLATE 
The silica gel in each of the bands was scraped off into separate test 
tubes, eluted with 4 ml of chloroform:methanol (9:1) by mixing on a 
vortex shaker and centrifuging at 3 000 r.p.m. for 10 min. An 
aliquot of the filtrate (3,5 ml) was evaporated to dryness and re-
dissolved in 0,2 ml of dichloromethane . Five pre-coated Merck 
5 x 20 cm plates were spotted with 10 ~l of each of these solutions 
according to the plan shown in Figures 60 and 61 . Pl ates 1, 2 and 
3 were developed in solvent system III and plates 4 and 5 were de= 
veloped in solvent system XV. They were examined under ultraviolet 
light and the fluorescent spots lightly outlined with a soft lead 
pencil as illustrated in Figures 60 and 61. 
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BAND B 
• 
BAND 7 
BAND 6 
, 
• 
BAND 5 
,
. 
• 
BAND 4 
--~----- -------: 
BAND 3 
BAND 2 
BAND 1 
Solvent System XXVI 
Fi g. 59 Chromatogram of Preparative Plate of Dichloromethane 
Extract of Urine ' from ' RatDosed with 14C Phenylbuta= 
~ 
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Pl a te 1 Plate 2 
Ring 0 
lactone ...................... 0 
form 
(j G 
0 0 
1 
Band Band di-OH Y-OH de= Band 
1 2 deri= ri va ti ve 3 
vative (straight 
chain hy= 
Solvent System III droxyl form) 
Fi g. 60 Chromatogram of Compounds Eluted from Preparative 
Pl ate Bands 1 - 5 Compared to Standards 
176 
Fig. 60 (conti nued) 
Plate 3 
o 0 
o 0 
Band Oxyphen= Band 
4 butazone 5 
Plate 4 
0 0 
G 
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Solvent System XV 
o 
• 
Straight 
c hoi" l\- - - - - - - -- - -hydroxyl 
Y-OH (ring Band 6 
1 actone 
form) de= 
rivative 
of phenyl= 
butazone 
form 
4-0H 
derivative 
of phenyl = 
butazone 
Pl ate 5 
o 
Phenyl= Band 
buta= 7 
zone 
Band 
8 
Fi g. 61 Chromatogram of Compounds Eluted from Preparative -Plate 
Bands 6 - 8 Compared to Standards 
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As demonstrated in Figures 59, 60 and 61 good separation had 
been achieved on the preparative plate except in Band 6 which containea 
a mixture of the Y-OH (ring lactone form) and 4-0H derivatives of 
phenylbutazone and these were separated by development in solvent 
system XV. Figures 60 and 61 also show the equilibration that took 
place between the ring lactone and straight chain hydroxyl forms of 
the Y-OH derivative of phenylbutazone. For this reason it was found 
feasible to quantitate the two forms collectively and not as two 
different entities. 
4. QUANTITATIVE DETERMINATION OF METABOLITES FROM TLC PLATES 
4.1 Quantitative Determination of Phenylbutazone, Its 
Y-hydroxy Derivative and Oxyphenbutazone 
The silica gel coating on the plate in each of the areas shown 
as outlined numbered spots 8, 5, 7 and 3 in Figures 60 and 61 
was scraped off into separate test tubes, eluted with 4 ml 
chloroform:methanol (9:1) by mixing on the vortex shaker and 
centrifuging at 3000 r.p.m. for 10 min. An aliquot (3 ml) of 
each of the filtrates was pipetted into spectrophotometric 
cuvettes and the absorbance measured at 270 nm. The contents 
of the cuvettes were transferred to l.s.c . vials together with 
the solvent used to wash out the cuvettes. Great care was taken 
to ensure that no radioactivity was lost during these transfers. 
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The solutions were evaporated to dryness, 10 ml of Aquagel added 
to each of the vials and the radioactivity of each measured. 
Table 44 records the rad -ioactivity of spots 8, 5, 7, and 3, 
representing phenylbutazone, oxyphenbutazone and the two molecu= 
lar forms of the Y-hydroxy derivative of phenylbutazone respec= 
tively, together with their concentrations as calculated from 
spectrophotometric data. 
Table 44 CONCENTRATION AND RADIOACTIVITY OF ELUTED COMPOUNDS ON 
CHROMATOGRAMS 
Spot Absorbance 
-1 ll~' Radio= 
Compound Number (270 nm) llg·ml 3 ml- 1 activity (in dpm) 
in 3 ml 
Phenyl butazone 8 47,5 37 III 205 
Oxyphenbutazone 5 51,5 37 111 929 
Y -Hydroxy derivati ve 
of phenylbutazone 7 9,0 3 9 1 045 
(ring lactone form) 
Y-Hydroxy derivative 
of phenylbutazone 3 32,0 16 48 4 535 (straight chain 
hydroxyl form) 
The weights of the radioactive phenylbutazone, oxyphenbutazone 
and the Y-hydroxy derivative of phenyl butazone in the 48 h urine 
of the rat dosed with 14C phenylbutazone were calculated using 
the formula in Figure 62. 
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W Weight of unlabelled compound 
Wr Weight of labelled compound 
SpB Specific activity of labelled phenylbutazone 
(10,84 KBq.mg-1) 
Sr Specific activity of mixed labelled and unlabelled 
compound 
Fig. 62 Formula used to Calculate Weights of Radioactive Compounds 
by Inverse Isotope Dilution Analysis 
4.2 Quantitative Determination of Minor Metabolites and 
Decomposition Products of Phenylbutazone 
The silica gel in the areas shown as numbered spots 1, 2, 4, 6 
and 9. in Figures 60 and 61 was extracted as described above, 
and 3 ml of each of the filtrates evaporated to dryness in l.s.c. 
vials, re-dissolved in 10 ml of Aquagel and their radioactivity 
measured. The weights of these minor metabolites and decompo= 
·sition products in 48 h urine were calculated by comparing their 
radioactivity with that of the major metabolite, the Y-hydroxy 
derivative of phenylbutazone. 
The weights of metabolites and decomposition products found in 
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the urine of rats dosed with 14C labelled phenylbutazone together 
with the percentage of the administered dose are shown in Table 45. 
Table 45 % DOSE RECOVERED OF COMPOUNDS ISOLATED FROM THE URINE 
OF A RAT -TREATED WITH 14C LABELLED PHENYLBUTAZONE 
Radioactivity Weight Percentage 
in dpm in in mg of dose in 
3 ml eluate in 48h 48h urine 
u~~ne 
Phenylbutazone 205 0,115 1,15 
Oxyphenbutazone 929 0,394 3,94 
Y-OH Derivative of phenylbutazone 5 570 3,570 35,70 
p-Y-DiOH derivative of 
phenylbutazone 34 0,022 0,22 
4-0H Derivative of phenylbutazone 76 0,049 0,49 
4-0H Derivative of oxyphen= 
butazone 296 0,18 1,8 
Compounds remaining at origin 35 0,022 0,22 
TOTAL 4,352 43,52 
DIS C U S S ION 
CHAPTER XIV 
DISCUSSION 
Although many derivatives of Pyrazolidine-3,5-di one have been exten= 
sively investigated as therapeutic agents (5 ,8,1 1,14,15, 24, 31, 44, 
48, 52, 54, 55, 56), surprisingly little comprehensive work has been 
done on their metabolism in various animal species and man (11, 12, 
13, 19, 26, 43). This was particularly true of phenylbutazone, one 
of the drugs of choice for the treatment of rheumatoid arthriti s, as 
in early 1974, when this study was instituted, no fresh information 
had been published since the work of Burns (13) in 1955 and Perel 
(43) in 1961. For this reason it was decided to investigate the 
pattern of metabolism of this drug in the rat. During the course 
of this work, Bakke (4) published a paper on the metabolism of 
phenylbutazone in the rat, and Dieterle (22), McGilveray (35) and 
Aarbakke (1) published their findings on the metabolism of phenylbuta= 
zone in humans, so it has been possible to compare their results with 
those in this paper. 
Early workers (13) in the field of metabolism of phenylbutazone did 
not have the advantages of the radio-chemical techniques now availa= 
ble; nevertheless, they did establish the formation of two metabo= 
lites, the p-hydroxy and the Y-hydroxy derivatives of phenylbutazone, 
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and their methods of quantitation for these metabolites gave results 
reasonably close to those of Dieterle (Table 46). 
Table 46 COMPARATIVE FIGURES OF % RECOVERY OF THE P-HYDROXY 
AND y-HYDROXY DERIVATIVES OF PHENYLBUTAZONE IN THE 
URINE OF MAN DOSED WITH PHENYLBUTAZONE 
% of Administered Drug 
Metabolite of Phenylbutazone 
Burns (1955) Di eterl e (1976) 
p-Hydroxy derivative of phenyl= 3 1,6 butazone (oxyphenbutazone) 
Y-Hydroxy derivative of 5 5,6 phenylbutazone 
Perel (43) reported the presence of the glucuronide of oxyphenbutazone, 
but was not able to isolate the C-4 glucuronides identified by 
Dieterle (22). 
A problem that arose during this i nvestigation was the tendency to 
decomposition of phenylbutazone and oxyphenbutazone during the course 
of experimentation. However , it was proved that phenylbutazone did 
not decompose detectably at room temperature in alkaline solution in 
3 days, and decomposition · was minimal during an incubation period of 
24 h in urine. The Rf value of the product of decomposition during 
incubation differed from that of the 4-hydroxy derivative which 
formed during chromatography on TLC plates within 15 min of spotting. 
1B4 
Bakke (4) overcame problems of oxidation by performing all tests in 
an atmosphere of nitrogen, but in this study it was found to be an 
unnecessary precaution provided plates were developed immediately 
after spotting. In preparative chromatography, using double develop= 
ment where compounds were in contact with the slightly acidic coating 
of TLC plates for a prolonged period of time, it was found that some 
decomposition occurred. The addition of sodium thiosulphate· to the 
slurry used for the preparation of these plates reduced the decompo= 
sition to a minimum by acting as an anti -oxidant (22). On the other 
hand, although oxyphenbutazone did not decompose in alkaline solution, 
two products of decomposition, one of which was its 4-hydroxy deriva= 
tive, were produced during incubation at 370 C. These resul ts 
indicated that the 4-hydroxy derivative of phenylbutazone found in 
the urine was probably a product of metabolism, whereas the 4-hydroxy 
derivative of oxyphenbutazone could be either an artifact formed by 
decomposition of the oxyphenbutazone in the bladder or a metabolite. 
It was found that oxidation of metabolites during the collection of 
urine and faeces could be reduced to a minimum by immersing the 
collection vessels of the Metabowl in methanol at -200 C. 
An early report (43) to th e effect that rats dosed wi th 14C phenyl = 
butazone excreted> 50'7. of thei r radi oacti vi ty in 0 - 24 h uri ne was 
confirmed by other workers (Bakke (4), Mathew (32)) and in this study. 
Table 47 shows that there was close agreement in the % dose recovered 
in the 0 - 4B h urine in these later studies. However, the table 
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also shows considerable disparity in the percentage dose recovered 
from the faeces by these workers. 
As can be seen in Table 47, Bakke (4) recovered a much higher % of 
the dose from the faeces. This higher result is surprising since 
his results were estimated in the dichloroethane extract of homogeni= 
sed faeces and no account was taken of possible water soluble meta= 
bolites present in the aqueous fraction of the faeces homogenate 
remaining after extraction. Furthermore, one would expect faecal 
excretion to consist mainly of water soluble conjugates of relatively 
high molecular mass. He also reported that excretion in faeces 
collected over a period of 24 h after dosing was almost twice as high 
as that in faeces collected from 24 to 48 h (22,9% and 11,8% respec= 
tively), whereas these studies showed the opposite to be the case; 
3,3% in faeces collected up to 24 h after dosing and 7,9% in 24 - 48 
h faeces. The higher value of excretion in the 24 - 48 h faeces 
found in these studies suggests that enterohepatic circulation is 
significant, a fact substantiated by studies in man (2~ illustrated 
in Figure 27. 
Bakke carried out excretion studies in male Wistar rats whereas the 
results by other workers shown in Table 47 are given for female 
Wistar rats. This could account for these discrepancies as it is 
recognised that there are sex differences in metabolism in rats (9). 
Unfortunately the facilities of gas chromatography and GCjMS were not 
Table 47 
Worker 
Mathew 
(3 rats) 
Bakke 
(5 rats) 
This study 
(4 rats) 
COMPARISON OF RESULTS OF EXCRETION STUDIES ON RATS TREATED WITH 1\ 
PHENYLBUTAZONE 
Percentage of Dose 
Specimen 
o - 24 h 24 - 48 h 48 - 72 h 72 - 96 h 
Urine 50,2 (46,8-52,5) 12,93 (12,8-13,1) 3,07 (1,9-2,8) 1,8 (1,0-3,0) 
Faeces 3,7 ( 3,6- 4,2) 4,33 ( 3,7- 5,4) 0,96 (0,8-1,2) 0,43 (0,3-0,5) 
Urine 54,3 (44,0-67,4) 6,5 ( 3,2- 8,9) 
Faeces 22,9 (16,3-34,0) 11,8 ( 6,8-17,2) 
Urine 53,53 (48,6-60,2) 14,18(11,6-19,8) 4,03 (3,3-5,2) 0,7 (0,4-1,0) 
Faeces 3,28 ( 0,6- 6,2) 7,92 (4,9-11,5) 2,33 (0,6-3,4) 0,73(0,4-1,1) 
-
~ -
-
TOTAL 
68 
9,42 
60.8 
34,7 
72,44 
14,26 
I 
..... 
co 
'" 
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available in this laboratory. However, the metabolites in urine were 
identified chromatographically on TLC plates and their Rf values and 
colour reactions compared with those of standard reference compounds. 
Two solvent systems were found to be necessary to separate the 
metabo 1 i tes sati sfactorily. These results were further confi rmed 
using autoradiography. 
Table 48 
Solvent 
XV 
III 
RELATIVE Rf VALUES AND COLOUR REACTIONS OF STANDARD 
COMPOUNDS 
Standard Compounds Relative Colour Rf Value Reaction 
Phenyl butazone 2,00 Green grey 
Y-Hydroxy (ring lactone form) 1,81 Vi 01 et derivative of phenylbutazone 
4-Hydroxy derivative of 1,41 Green grey phenylbutazone 
Oxyphenbutazone 1,00 Yell ow 
Oxyphenbutazone 1,00 Yell ow 
4-Hydroxy derivative of 0,80 Yell ow oxyphenbutazone 
Y-Hydroxy (straight chain hydroxyl 0,55 Brown form) derivative of phenylbutazone Orange 
p-Y-Dihydroxy derivative of 0,31 Yellow phenyl butazone 
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Table 48 shows that the major metabolite in urine, the Y-hydroxy de= 
rivative of phenylbutazone, is present in both its molecular forms. 
The product of microsomal metabolism is probably the straight chain 
hydroxyl form, part of which lactonises to form an equilibrium mixture. 
In this study it has been shown that this equilibrium mixture can be 
separated chromatographically into the more polar straight chain 
hydroxyl form and the less polar ring lactone form. Autoradiography 
showed conclusively that both forms were present in the urine of rats 
treated with 14C phenylbutazone . Although it is well known that 
~-hydroxy compounds exist in two molecular forms (20) no cognisance 
was taken by other workers of the fact that they have different 
polarities and therefore different Rf values on TLC plates. 
The aqueous fraction remaining after extraction of urine with dichloro-
methane was found to contain hydrolysable and non-hydrolysable com= 
pounds. The water insoluble compounds obtained f rom the enzymatic 
hydrolysate of this aqueous fraction were oxyphenbutazone and its 
4-hydroxy derivative . The latter was most probably an artifact 
formed during hydrolysis. As the enzyme system used for hydrolysis 
was a mixture of beta-glucuronidase and aryl-sulphatase, it was not 
possible to determine whether the conjugates were beta-glucuronides 
or sulphates. By comparison with the findings of other workers 
they were probably mainly glucuronides (4) . Unhydrolysable water 
soluble compounds remaining in the aqueous fraction were detected 
but could not be identified. 
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Faeces was also found to contain metabolites and decomposition pro= 
ducts. Enzymatic hydrolysis of faeces homogenates showed that the 
greater percentage of these pl'oducts could not be hydrolysed by beta-
glucuronidase/aryl-sulphatase. The hydrolysable products, however, 
were found to be either the beta-glucuronide or aryl-sulphate of 
oxyphenbutazone and its 4-hydroxy derivative. 
For quantitation of metabolites, the method of multiple inverse isotope 
dilution analysis reported by Dieterle (22) was used. This prov~ ~ 
be a useful and accurate method of quantitating the major metabolites, 
using a combination of spectrophotometry and liquid scintillation 
spectrometry. The minor metabolites and decomposition products were 
quantitated by comparing their radioactivity with that of the 
Y-hydroxy derivative of phenylbutazone, the major metabolite . 
In the method of Bakke (4), phenylbutazone and oxyphenbutazone were 
quantitated by crystallisation and l i quid scintillation spectrometry, 
and the amounts of other metabolites and decomposition products were 
estimated by measurement of the radioactivity of the individual com= 
pounds and comparing these with the tota l radioactivity in the urine 
(Table 49). Table 49 shows that there was close agreement in the 
total percentage of metabolites recovered by Bakke (4) and in this 
study. 
However, there is a significant difference between the amounts of 
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Table 49 QUANTITATION OF COMPOUNDS PRESENT IN THE URINE OF 
RATS TREATED WITH 14C LABELLED PHENYLBUTAZONE, 
EXPRESSED AS PERCENTAGE RECOVERY OF DOSE 
Compound Bakke This Study 
Phenylbutazone 0,4 1,15 
Oxyphenbutazone 1,6 3,94 
Y-Hydroxy derivative of phenylbutazone 25,4 35,70 
p-y-Dihydroxy derivative of phenylbutazone 10,2 0,22 
4-Hydroxy derivative of phenylbutazone - 0,49 
4-Hydroxy derivative of oxyphenbutazone 1,8 1,80 
--
39,4 43.32 
individual metabolites reported by him and those found in the present 
study. He reported the p-Y"di hydroxy deri vati ve of phenyl butazone 
as a major urinary metabolite (10,2%) whereas these studies indicate 
that it is , only a minor metabolite (0,22%) (Table 49). Repetition 
of the chromatographic procedure reported by Bakke for the identifi= 
cation of metabolites showed that the substance he reported as a 
major metabolite and named the p-Y-dihydroxy derivative of phenylbu= 
tazone was in all probability the straight chain hydroxyl isomer of 
the Y-hydroxy derivative of phenylbutazone (Table 50). 
It can be seen from Table 50 that there would be practical difficulties 
in identifying these two compounds using the solvent systems he has 
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Table 50 RELATIVE Rf VALUES OF STANDARD COMPOUNDS USING 
BAKKE'S SOLVENT SYSTEMS (4) 
Dichloro= Cyclohexane 
ethane: chloroform: Standard Compound acetone methanol: acetic acid 
(9:1) (60:30:5:5) 
Phenyl butazone 2,10 2,55 
V-Hydroxy (ring lactone form) 1,40 1,00 derivative of phenylbutazone 
4-Hydroxy derivative of 1,27 1,21 phenylbutazone 
Oxyphenbutazone 1,00 1,00 
4-Hydroxy derivative of 0,34 0,56 oxyphenbutazone 
V-Hydroxy (straight chain hydroxyl form) 0,24 0,19 derivative of phenylbutazone 
p-Y-Dihydroxy derivative of 0,00 0,19 phenylbutazone 
quoted. Further evidence in support of this view is that the com= 
bined % of the V-hydroxy and p-Y-dihydroxy derivatives of phenylbuta= 
zone reported by him is almost identical to the % of the combined 
isomers of the V-hydroxy derivatives found in this study (Table 49). 
Furthermore, it would seem unlikely that microsomal hydroxylation 
waul d fo ·11 ow a pathway 1 eadi ng to the di hydroxyl ated deri vati ve as a 
major metabolite when an easily excreted monohydroxylated metabolite 
can be formed by a single metabol i c process . 
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There is a disparity between the % dose recovered in 48 h urine 
(69,5%) found in the excretion studies and the % dose recovered by 
the method outlined for quantitation of metabolites (43,5%). This 
difference can be explained by the fact that only water insoluble 
metabolites were quantitated by the latter method. 
In his studies on the metabolism of phenylbutazone in man, Dieterle 
(22) reported the major metabolites in the urine to be C-4-glucuroni= 
des of phenylbutazone and its Y-hydroxy derivative . They were re= 
sponsible for about 40% and 12% respectively of the urinary radio= 
activity. In contras~ the present study of the metabolism in rats 
has shown that the non-conjugated compounds were the major urinary 
metabolites. This is a good example of species variation in drug 
metabolism and confirms that, though the study of drug metabolism 
in animals is important, the results of these studies cannot be 
taken as representative of the metabolic pattern in man. 
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